Venous thromboembolism and cancer by Gran, Olga Vikhammer
Venous thromboembolism and cancer 
Olga Vikhammer Gran
A dissertation for the degree of Philosophiae Doctor




Table of Contents 
Table of Contents .............................................................................................................. 1 
Acknowledgements .......................................................................................................... 3 
List of papers .................................................................................................................... 5 
Summary .......................................................................................................................... 6 
Sammendrag .................................................................................................................... 7 
Abbreviations ................................................................................................................... 8 
1. Introduction ................................................................................................................ 10 
1.1 Epidemiology .................................................................................................................... 12 
1.1.1 Venous thromboembolism in the general population ......................................................... 12 
1.1.2 Recurrent venous thromboembolism in the general population ........................................ 14 
1.1.3 Venous thromboembolism in cancer patients ..................................................................... 15 
1.2 Pathophysiology ............................................................................................................... 18 
1.2.1 General pathophysiology of venous thromboembolism...................................................... 18 
1.2.2 Pathophysiology of cancer-related venous thromboembolism ........................................... 21 
1.3 Risk factors ....................................................................................................................... 22 
1.3.1. Risk factors for venous thromboembolism ......................................................................... 23 
1.3.2 Patient-related risk factors for venous thromboembolism in cancer .................................. 27 
1.3.3 Cancer-related risk factors for venous thromboembolism in cancer .................................. 29 
1.3.4 Treatment-related risk factors for venous thromboembolism in cancer ............................ 31 
1.3.5 Biomarkers of venous thromboembolism in cancer ............................................................ 33 
1.3.6 Risk factors for recurrent venous thromboembolism .......................................................... 35 
1.3.7 Risk factors for recurrent venous thromboembolism in cancer .......................................... 36 
1.4 Risk of cancer after venous thromboembolism .................................................................. 38 
1.4.1 VTE as a first sign of cancer .................................................................................................. 38 
1.4.2 Screening for cancer in patients with venous thromboembolism ....................................... 39 
2. Aims of the thesis........................................................................................................ 41 
3. Methods ..................................................................................................................... 42 
3.1 Study populations ............................................................................................................. 42 
3.1.1 The Tromsø Study ................................................................................................................. 42 
3.1.2 The Scandinavian Thrombosis and Cancer Cohort ............................................................... 43 
3.2 Baseline measurements .................................................................................................... 44 
3.3 Outcome measures ................................................................................................... 46 
3.3.1 Identification and validation of venous thromboembolic events ........................................ 46 
3.3.2 Identification and validation of cancer ................................................................................. 47 
3.3.3 Definition of active cancer.................................................................................................... 48 
4. Main results ................................................................................................................ 50 
4.1 Paper I .............................................................................................................................. 50 
2 
 
4.2 Paper II ............................................................................................................................. 51 
4.3 Paper III ............................................................................................................................ 52 
4.4 Paper IV ............................................................................................................................ 53 
5. General discussion ...................................................................................................... 54 
5.1 Methodological considerations .......................................................................................... 54 
5.1.1 Study design ......................................................................................................................... 54 
5.1.2 Bias ....................................................................................................................................... 56 
5.1.3 Competing risk of death ....................................................................................................... 59 
5.1.4 Confounding ......................................................................................................................... 62 
5.1.5 Interaction ............................................................................................................................ 64 
5.1.6 External validity .................................................................................................................... 65 
5.2 Discussion of main results ................................................................................................. 68 
5.2.1 Joint effects of F5 variants and cancer on the risk of venous thromboembolism (Paper I) 68 
5.2.2 Cancer-related VTE in the general population (Paper II) ..................................................... 70 
5.2.3 Recurrent venous thromboembolism and mortality after overt and occult cancer related 
venous thromboembolism (Paper III) ........................................................................................... 72 
5.2.4 D-dimer levels at venous thromboembolism and risk of subsequent cancer (Paper IV) ..... 76 
6. Conclusions ................................................................................................................. 78 
7. Implications of results and further perspectives .......................................................... 80 







The work of this thesis was carried out at K.G. Jebsen Thrombosis Research and Expertise Center 
(TREC), Department of Clinical Medicine at the UiT – The Arctic University of Norway from August 2014 
until May 2017. My PhD period has been funded by the K.G. Jebsen Foundation and UiT – The Arctic 
University of Norway.  
The completion of this thesis is thanks, in a large part, to the special people who challenged and 
supported me along the way.  
First and foremost, I want to express my deepest gratitude to my main supervisor, Professor John-
Bjarne Hansen. I am tremendously fortunate to have stumbled upon such a supportive and dedicated 
boss. Your passion and knowledge in the field never ceases to amaze me, and I truly wish I will be as 
passionate about anything in life as you are about VTE! Thank you for your encouraging chats about 
science and life over coffee on Sunday mornings at the office, and for keeping a sense of humor when 
I had lost mine. Your patience, optimism and corny jokes have made TREC a really enjoyable place to 
work.  
Second, my sincere thanks go to my co-supervisor, Associate Professor Sigrid Kufaas Brækkan. Thank 
you for sharing your knowledge of statistics and epidemiology with me and for your incredible patience 
while doing so. Even with a tremendously busy schedule, you’re always so willing to help when I come 
knocking at your office door with a question. Your always cheerful disposition, constant smiles and 
singing may just make you the happiest researcher on the planet! 
I would also like to direct a special thanks to Gro Grimnes and Lars Horvei, my office mates and the 
original members of “the office of rejection” and our new office member, Line Evensen. I have lost 
count of how many times you guys have helped me out of near research-induced meltdowns. I honestly 
think that this thesis was only possible thanks to your constant encouragement. I will really miss our 
(not-always so scientific) chats and laughs, but I’m sure you’ll get a lot more work done with me out of 
the office. I’d also like to thank my former office mate, Hilde Jensvoll, for taking me under her wing 
and showing me the ropes of research when I first started at TREC. 
I must also thank TREC’s advisor, Helle Jørgensen. Thank you for your help with all things administrative 
– I’m not sure how the group would be able to function without you! To my PhD student minions, 
Hanne Skille and Benedikte Paulsen, it’s been a real pleasure working closely with you, as one of your 
supervisors and on the official TREC party planning committee. In my daily work, I have also been 
blessed with a group of fantastic colleagues and I am  grateful to all the past and present members of 
4 
 
TREC (Nadia Arshad, Sara Bechstein, Esben Bjøri, Jan Brox, Trond Børvik, Trygve Sølberg Ellingsen, Erin 
Mathiesen Hald, Kristian Hindberg, Ina Høiland, Trond Isaksen, Simin Jamaly, Søren Beck Jensen, Håkon 
Sandbukt Johnsen, Jostein Lappegård, Nadezhda Latysheva, Gunhild Lerstad, Robin Liang, Caroline 
Lind, Dana Meknas, Cathrine Ramberg, Ludvig Balteskard Rinde, Birgit Småbrekke, Timofey 
Sovershaev, Irina Starikova, Anders Vik, Line Wilsgård,  Bjarne Østerud). I have you all to thank for the 
countless new “TREC-English” words and phrases I have picked up for the last few years. I cannot wait 
to start incorporating “Christmas table”, “earth mother”, “silent long jump”, “out-of-patient death” 
and “cook soup on a nail” into my every day vocabulary! When I think back on my years at TREC with 
the wine lottery, TRECxercise, office parties, the Hollmenkollen relay, trips to Toronto and The Hague, 
Sommarøya seminars, ski days and even a movie premiere – I almost want to do it all over again.   
And behind everything, throughout this entire journey, I have benefitted immensely from the support 
of my friends and family. To my mom and dad, Renata and Kris, thank you for the unconditional love, 
support and friendship you have always given me. While I could expound on your impact on my life for 
several more pages, I can just as easily summarize your meaning to me in a single sentence: a kid 
couldn’t ask for a better Mom and Dad. To my sisters and partners-in-crime, Ewa and Magda, thank 
you for being the most supportive, loving best friends that a girl could ask for!  
Finally, thank you to my dear husband Mads. You have been my worst distraction, my voice of reason, 
and my biggest cheerleader throughout this entire PhD journey. Long days at work aren’t all that bad 
when I get to come home to you. I love doing life with you. Thanks to my dog, Bear, for fluffy doggy 
cuddles when I’ve needed them most and for bodyguard services while walking through the dark 
university corridors after late evenings at the office. And last, but certainly not least, I want to thank 
my unborn baby, who has truly been my greatest encouragment and motivation during the rigors of 
thesis writing these last months. I cannot wait to meet you, kiddo.  
Olga  




List of papers 
I. Joint effects of cancer and variants in the factor 5 gene on the risk of venous 
thromboembolism.  
Gran OV, Smith EN, Brækkan SK, Jensvoll H, Solomon T, Hindberg K, Wilsgaard T, Rosendaal 
FR, Frazer KA, Hansen JB. 
Haematologica. 2016 September; 101(9): 1046-53. 
 
II. Impact of time since diagnosis and mortality rate on cancer-associated venous 
thromboembolism in a general population – the Scandinavian Thrombosis and Cancer 
(STAC) cohort. 
Blix K, Gran OV, Severinsen MT, Cannegieter S, Jensvoll H, Overvad K, Hammerstrøm J, 
Tjønneland A, Næss IA, Brækkan SK, Rosendaal FR, Kristensen SR, Hansen JB 
Manuscript 
 
III. Occult cancer-related first venous thromboembolism is associated with an increased risk 
of recurrent venous thromboembolism. 
Gran OV, Brækkan SK, Paulsen B, Skille H, Rosendaal FR, Hansen JB. 
Journal of Thrombosis and Haemostasis; 2017 April; 10.1111/jth.13714 
 
IV. D-dimer measured at first venous thromboembolism is associated with future risk of 
cancer. 
Gran OV, Brækkan SK, Paulsen B, Skille H, Hansen JB. 




 Venous thromboembolism (VTE) is a collective term for deep vein thrombosis and pulmonary 
embolism. VTE is a common cause of mortality and morbidity in patients with cancer, and may also be 
the first sign of an underlying malignancy. The first aim of this thesis was to investigate the risk of 
incident and recurrent VTE in active cancer compared to a cancer-free reference population and to 
explore the influence of genetic risk factors on cancer-related VTE. Secondly, we aimed to investigate 
the association between plasma D-dimer levels at VTE and the subsequent risk of cancer.  
 All four papers in this thesis utilize the Tromsø Study. The first survey of the Tromsø Study was 
conducted in 1974 and, thus far, seven surveys have been completed. Our study populations were 
recruited from the Tromsø 4 and 6 surveys for Paper I, and Tromsø 1 to 6 surveys for Papers III and IV. 
Participants were followed from 1994, when the VTE registry was established in Tromsø, throughout 
2012. Paper II was based on the Scandinavian Thrombosis and Cancer (STAC) cohort, which comprises 
individual data from the Tromsø 4 survey, the second Nord-Trøndelag Health Study (HUNT2) and the 
Danish Diet, Cancer and Health (DCH) Study. Validated VTE events and cancer diagnoses were 
registered from inclusion (1993 to 1997) to the end of follow-up (2007 to 2012). 
 We found a joint effect between two single nucleotide polymorphisms (SNPs) in the F5 gene 
(F5 rs6025 (Factor V Leiden) and F5 rs4524) and active cancer on the risk of VTE. The incidence of 
cancer-related VTE increased considerably in the six months following a cancer diagnosis, and 
especially so in patients with risk alleles at these SNPs.  
Further, cancer-related factors consistently demonstrated a strong influence on incident and 
recurrent VTE. In traditional analysis, the risk of VTE was highest in the first 6 months after cancer 
diagnosis and the risk declined markedly thereafter. However, when mortality was taken into account, 
the risk of VTE was equal in the 6 months before and 6 months after a cancer diagnosis, which suggests 
that cancer itself is a major contributor to the VTE risk. The risk of VTE by cancer sites was greatly 
influenced by mortality and the time since cancer diagnosis. We found that patients with an occult 
cancer-related incident VTE had a higher rate of VTE recurrence than those with overt cancer and those 
without cancer. Patients with occult cancer-related incident VTE who experienced a VTE recurrence 
more often had prothrombotic and advanced cancers at the time of cancer diagnosis. The majority of 
VTE recurrences were not related to cancer treatment as they occurred prior to cancer diagnosis.  
Finally, we found that plasma D-dimer levels above 5000 ng/ml at incident VTE were associated 
with an increased risk of subsequent cancer at one and two years. Patients with higher D-dimer levels 
at incident VTE had more advanced cancers at the time of diagnosis and mortality was greater among 




Venøs tromboembolisme (VTE) er fellesbetegnelsen for dyp venetrombose og lungeemboli. 
VTE er en vanlig årsak til morbiditet og mortalitet blant kreftpasienter, og kan i tillegg være et tidlig 
tegn på underliggende malignitet. Formålet med denne avhandlingen var å undersøke risikoen for 
førstegangs- og residiverende VTE ved aktiv kreftsykdom sammenlignet med en kreftfri 
referansepopulasjon, og å undersøke hvordan genetiske risikofaktorer påvirker VTE. Videre ville vi 
undersøke assosiasjonen mellom plasma D-dimer ved VTE diagnose og påfølgende risiko for kreft. 
Alle fire artikler i denne avhandlingen benytter data fra Tromsøundersøkelsen. Den første 
Tromsøundersøkelsen ble gjennomført i 1974 og så langt har 7 undersøkelser blitt utført. 
Studiepopulasjonen i artikkel I ble rekruttert fra Tromsø 4 og 6. For artikkel III og IV benyttet vi 
undersøkelsene 1 til 6. Deltakere ble fulgt fra 1994, da VTE-registeret ble etablert, ut desember 2012. 
Artikkel II er basert på «the Scandinavian Thrombosis and Cancer (STAC)» kohorten, som inkluderer 
individuelle data fra Tromsø 4, den andre Helseundersøkelsen i Nord-Trøndelag (HUNT2) og den 
danske «Diet, Cancer and Health» (DCH) studien. Validerte VTE- og kreftdiagnoser ble registrert fra 
inklusjonsperioden (1993 -1997), til og med oppfølgingsperioden (2007-2012). 
To genetiske varianter (single nucleotide polymorphism, SNP) i FV genet (F5 rs6025 (Faktor V 
Leiden) og F5 rs4524) i kombinasjon med aktiv kreftsykdom, hadde en synergistisk effekt på risikoen 
for VTE. Insidensen av kreftrelatert VTE økte betydelig i de første 6 månedene etter en kreftdiagnose, 
og spesielt blant pasienter med risikoalleler av disse SNPene. I tillegg hadde kreftrelaterte faktorer som 
type kreft og metastasegrad en sterk innvirf2010kning på risikoen for førstegangs- og residiverende 
VTE. Ved bruk av tradisjonelle analysemetoder fant vi at risikoen for VTE var høyest de første 6 
månedene etter kreftdiagnosen. Men, når vi tok høyde for mortaliteten blant disse pasientene, var 
risikoen for VTE den samme i perioden 6 måneder før og 6 måneder etter kreftdiagnosen, hvilket 
antyder at kreftsykdommen alene har stor innvirkning på VTE-risikoen. Videre var risikoen for VTE ved 
ulike krefttyper sterkt påvirket av mortalitet og tid siden kreftdiagnosen. Vi oppdaget at VTE pasienter 
med okkult kreft hadde høyere forekomst av residiverende VTE enn både de med diagnostisert 
kreftsykdom og kreftfrie pasienter. Pasienter med okkult kreft som fikk residiverende VTE hadde oftere 
protrombotisk og avansert kreftsykdom når kreftdiagnosen ble stilt. De fleste VTE residivene var ikke 
relatert til kreftbehandling da de inntraff før kreftsykdommen ble oppdaget. 
Til slutt fant vi at plasma D-dimer nivå over 5000 ng/ml ved førstegangs VTE var assosiert 
med økt risiko for kreft både ett og to år etter VTE en VTE hendelse. Pasienter med høyt D-dimer nivå 
ved førstegangs VTE hadde i større grad avansert kreftsykdom ved diagnosetidspunktet, og 
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Venous thromboembolism (VTE) is a collective term for deep vein thrombosis (DVT) and 
pulmonary embolism (PE). DVT is the formation of a blood clot in the deep veins which may obstruct 
venous blood flow. DVT most commonly occurs in the large veins of the leg or thigh, but can also occur 
in other parts of the body. Classical symptoms and signs of DVT are pain, swelling and redness of the 
affected extremity. Traditionally, PE is thought to be a complication of DVT. PE primarily occurs when 
all, or parts, of the deep venous clot breaks free (embolizes). The clot then travels via the blood stream, 
through the right side of the heart and into the lungs, where it becomes lodged and prevents the flow 
of blood. However, the origin of PE remains undetected in up to 50% of patients with PE.1,2 PE is 
traditionally characterized by dyspnea, tachypnea, pleuritic-type chest pain, coughing and, in severe 
cases, circulatory collapse and death. DVTs account for approximately two-thirds of all VTE events, 
while PEs make up about one-third, although the two conditions often exist concurrently.3 
 Historically, the French doctor, Armand Trousseau, is credited with originally describing the 
relationship between VTE and cancer in 1865.4 However, it was actually another French physician, 
Jean-Baptiste Bouillard, who first described an association between thrombosis and cancer in 1823 – 
nearly half a century earlier than Trousseau.5 Nevertheless, the spontaneous formation of a venous 
thrombus in association with an underlying cancer has been termed Trousseau’s syndrome. 
Trousseau's syndrome is especially well-known in the field of medicine because only two years after 
Armand Trousseau described the condition, he diagnosed himself with a VTE secondary to gastric 
cancer, before succumbing to the illness shortly after.4 Since the time of Bouillard and Trousseau, 
several publications have confirmed the two-way relationship between malignancy and VTE.6,7 Today, 
cancer is established as one the strongest risk factors for VTE, and it is associated with a four- to seven-
fold higher risk of VTE, when compared to cancer-free subjects.8 Approximately 15% of cancer patients 
will develop a symptomatic VTE during the course of their disease and up to 50% have a VTE at 
autopsy.9 Clinical consequences of VTE are typically more common and more severe in cancer patients, 
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and the risk of death following a VTE is higher in cancer patients than in cancer-free subjects.10 With 
the use of prophylactic anticoagulants, VTE is a potentially preventable disease. Current guidelines, 
however, do not recommend blanket thromboprophylaxis to all cancer patients, as the risk of bleeding 
on anticoagulants is high in cancer patients.11 Thus, it is important to identify cancer patients who are 
at high risk of VTE, to determine who would most benefit from targeted thromboprophylaxis. 
 VTE can be the first manifestation of cancer, and up to 10% of patients with an unprovoked 
VTE are diagnosed with cancer within the first year.12 The risk of cancer is highest in the first year 
following a VTE event, but persists for several years thereafter.6,13 In recent years, there has been an 
ongoing debate regarding to what extent it is pertinent to screen for cancer in patients with an 
unprovoked VTE, as it is not apparent if earlier detection of cancer favors a patient’s prognosis. Thus, 
the understanding of both risk factors for VTE in cancer and cancer in VTE are fundamental for further 
understanding of the association between cancer and VTE.  
 There is a great need to further explore established risk factors and to identify novel risk factors 
for cancer-related VTE. Risk factors for cancer-related incident and recurrent VTE, as well as the two-





1.1.1 Venous thromboembolism in the general population 
Although VTE is the third most common cardiovascular disease worldwide, it is relatively 
neglected compared to myocardial infarction and stroke.14 Venous thromboembolism occurs in 1 to 2 
per 1000 individuals annually in developed countries, and based on European data, the estimated 
annual burden of symptomatic VTE in 25 European countries exceeds 1.6 million.15 Furthermore, it is 
estimated that there are approximately 540 000 VTE-related fatalities in Europe each year, which is 
double the combined deaths due to AIDS, breast cancer, prostate cancer and transport accidents.15,16 
Since the 1980s, the incidence of VTE is increasing, owing primarily to the substantial increase of the 
incidence of PE.17 In the Tromsø Study, the age-adjusted incidence rates (IR) of PE per 100 000 person-
years increased from 45 (95% confidence interval (CI) 23–67) in 1996/1997 to 113 (95% CI 82–144) in 
2010/2011.18  
VTE events can be classified into provoked and unprovoked, depending on the presence of risk 
factors at the time of the VTE event.19 Provoked events can occur in the presence of transient or 
persistent clinical risk factors, and transient risk factors are further classified into major and minor.20 
Provoked VTE events can occur in the presence of major transient risk factors (i.e. surgery with general 
anesthesia >30 min, Cesarean section) in the 3 months before an event, or by minor transient risk 
factors (i.e. surgery with general anesthesia <30 min, estrogen therapy, pregnancy) in the 2 months 
before a VTE diagnosis.20 VTE events may also be provoked by persistent risk factors, such as active 
cancer or any other on-going non-malignant condition associated with at least a 2-fold risk of recurrent 
VTE after stopping anticoagulant therapy (i.e. inflammatory bowel disease).20 Unprovoked events are 
VTEs that occur in the absence of a provoking risk factor, transient or persistent. VTE in the presence 
of provoking factors is generally associated with lower recurrence rates and does not normally warrant 
prolonged treatment with anticoagulants.19,21 However, persistent provoking risk factors (i.e. active 
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cancer) are associated with higher VTE recurrence rates than unprovoked VTEs.20 Population-based 
studies estimate that about 50 to 60% of VTEs are associated with provoking factors.22-24  
Short-term complications of VTE include thrombus extension or further embolization, VTE 
recurrence in the weeks to months following the initial event, and death. VTE may also lead to serious 
long-term complications such as post-thrombotic syndrome (PTS), chronic thromboembolic pulmonary 
hypertension (CTPH) and late recurrence.25 PTS is the most common complication of DVT, affecting 
between 20 to 50% of patients with lower limb DVTs.26,27 PTS typically causes chronic pain, swelling 
and skin changes in the affected leg. In severe cases, 10% may also develop venous leg ulcers, which 
can be very difficult to treat.26,28 Risk factors for PTS include female sex, obesity, proximal DVT location, 
recurrent DVTs and varicose veins, whereas cancer, surgery, plaster casts or inherited thrombophilias 
(i.e. FVL, PT 20210A) have not been found to influence the risk of PTS.26,29,30 PTS adds significantly to 
the cost of VTE treatment, places greater demands on the healthcare system and impairs patient 
mobility and quality of life.27,31 Furthermore, a Norwegian study found that DVT was associated with a 
60% increased risk of disability pension, while no significant association was seen for PE, and the most 
common and debilitating complication of DVT is PTS.32 CTPH is caused by chronic obstruction of major 
pulmonary arteries, causing the right side of the heart to work harder than normal due to the 
abnormally high blood pressure in the arteries of the lungs. CTPH complicates approximately 2 to 4% 
of acute PE events and is characterized by dyspnea, chest discomfort and signs of right-sided heart 
failure.33,34  
VTE is a major cause of morbidity and mortality. A recent Norwegian study including 710 
subjects with an incident VTE, reported an overall cumulative mortality rate of 8.6% (95% CI 6.7-11.0) 
at 30 days and 24.2% (95% CI 21.2-27.6) at one year.35 These results are in line with a large Canadian 
study of 67 354-definite and 35 123-probable VTEs that reported 30-day and 1-year case-fatality rates 
of 10.6% (95% CI 10.4-10.8) and 23.0% (95% CI 22.8-23.3), respectively.36 Mortality rates among 
subjects with unprovoked VTE events are lower than in subjects with provoked events, which is likely 
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explained by a higher age and the presence of additional comorbidities among those with provoked 
VTE.35 Furthermore, mortality rates are also higher among those with cancer.35,37 Almost 25% of all PE 
cases are thought to present as sudden death.38 Distinguishing sudden, fatal PE events is, however, a 
challenge as autopsies are not often performed in these patients, and therefore, these deaths are 
frequently mistakenly attributed to cardiac causes.39  
 
1.1.2 Recurrent venous thromboembolism in the general population 
VTE is a chronic disease that frequently recurs. Anticoagulation is thought to treat the acute 
thrombotic event, although it does not cure the underlying pro-thrombotic predisposition.40 The risk 
of VTE recurrence after an incident VTE is 5 to 7% per year, and the risk of VTE after an incident VTE is 
more than 50 times higher than in patients without a previous VTE event.3 The incidence of recurrent 
VTE is reported to be 7 to 10% at 6 months, 11 to 18% after 1 year, and 30 to 40% after 10 years.40-42 
Another study reported the two-year incidence of recurrent VTE to be 7.7% overall, and 14.2% in 
patients with cancer.24 VTE events tend to recur as the same clinical type as the initial event. Meaning 
that a patient with a DVT is more likely to suffer from a recurrent DVT, and a patient with a PE is more 
likely to suffer from a recurrent PE.40,43  
Independent clinical predictors of VTE recurrence include male sex, increasing age and body 
mass index, active cancer, neurologic disease with extremity paresis, and neurologic surgery.40 The risk 
of recurrence is lower in patients with events provoked by transient risk factors.21 Several risk 
prediction models exist for risk stratification for recurrent VTE such as the Vienna prediction model, 
the DASH score and the Rodger score.44-46 This risk prediction models include a combination of patient 
characteristics (i.e. sex, age, obesity, hormone use), VTE characteristics (i.e. DVT location, presence of 
redness or edema), and laboratory parameters (i.e. D-dimer levels) as predictive variables. 
Furthermore, recurrent VTE is associated with a substantially higher likelihood of post-thrombotic 
syndrome and chronic pulmonary hypertension.47  
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1.1.3 Venous thromboembolism in cancer patients 
VTE is a frequent and severe complication of cancer, and several studies have confirmed that 
20 to 30% of all incident VTE events in the general population are cancer-related.7,22,48 Active cancer is 
associated with a 4 to 7-fold increased risk of VTE, when compared to cancer-free subjects.49-51 The 
absolute risk of cancer-related VTE has been reported between 1 to 12%.52-54 The wide range of 
reported cumulative incidences is due to the heterogeneity of these studies, and may be a result of 
differences in the study populations, follow-up duration, definitions of active cancer and the VTE 
identification and validation criteria.  
The incidence of VTE in cancer is increasing.55,56 A large cohort study with registry data on over 
660 000 subjects found that the overall incidence of cancer-related VTE increased from 10 (95% CI 8-
14) per 1000 person years in 1997 to 19 (95% CI 18-21) per 1000 person years in 2006, while the same 
trend was not observed in cancer-free subjects.55 Improvements in the clinical and public awareness 
of cancer-related VTE and more aggressive cancer treatments (i.e. anti-angiogenic drugs, and surgery 
in later stages of cancer) were attributed as the main contributors to the increase in the incidence 
rates. Furthermore, increased utilization of improved non-invasive diagnostic imaging for the 
detection and staging of cancers, may identify incidental VTE events.  
 Clinical consequences of VTE such as recurrence, PTS, CTPH, as well as treatment-related 
bleeding complications are typically more common and more severe in cancer patients than in patients 
without. The American College of Chest Physicians (ACCP) guidelines recommend patients with cancer-
related VTE extended anticoagulation (no scheduled stop date) over 3 months of therapy for patients 
at a low (Grade 1B) and high (Grade 2B) bleeding risk.19 However, treatment failure despite adequate 
anticoagulation occurs frequently in patients with cancer and subsequently, cancer patients are at a 2 
to 9-fold higher risk of VTE recurrence compared to cancer-free subjects.40,57-59 In a cohort study of 477 
Olmsted county residents with cancer-related incident VTE, the cumulative incidence of VTE 
recurrence in cancer-related VTE was 18.0% at three months and 26.7% at one year.60 This study also 
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reported that cancer patients are at an increased risk of anticoagulant-associated bleeding and the 
cumulative incidence of major bleeding while on anticoagulation was 2.5% at three months and 4.7% 
at one year.60 Survival was significantly worse in cancer patients with recurrent VTE and with bleeding 
on anticoagulation. Furthermore, this study also found that tumor site (brain, lung, ovarian and 
pancreatic cancers, and myeloproliferative and myelodysplastic disorders), stage (stage IV, cancer 
stage progression) and leg paresis were independent predictors of VTE recurrence.  
 Cancer patients with VTE have reduced survival compared to cancer patients without VTE. In 
a Danish population-based study, the one-year survival rate was 12% in patients with cancer-related 
VTE, compared to 36% in cancer patients without a VTE.61 A study utilizing the California Cancer 
Registry (CCR) between 1993 and 1995, found that after adjustment for age, race, and cancer stage, 
VTE was a significant predictor of decreased one-year survival at all cancer sites (hazard ratios (HRs) 
1.6-4.2).52 Increased mortality was present in localized, regional and metastatic-stage cancers, 
however, metastatic disease was the strongest predictor of death. The majority of VTE-associated 
deaths occurred in the first 90 days following the VTE event.52 This suggests that the cause of death 
may be due to the VTE event (i.e. massive pulmonary embolism) or its treatment (anticoagulant-
related bleeding), or it may simply reflect the extent of cancer in these patients and/or the presence 
of comorbid conditions.  
 Studies have suggested that the use of prophylactic anticoagulants in cancer patients may 
improve quality of life and survival. Low molecular weight heparins (LMWH) are the anticoagulants of 
choice for primary prophylaxis and treatment of VTE in cancer patients.19,62,63 The effect of 
thromboprophylaxis in ambulatory cancer patients receiving chemotherapy has been summarized in a 
recent Cochrane review from 2016 which included results from 26 randomized control trials.64 During 
a median follow-up of 10 months, thromboprophylaxis with LMWH was found to be associated with a 
reduced risk of symptomatic VTE across different cancer types (relative risk (RR) 0.54, 95% CI 0.38-
0.75), with a reduction of 33 (95% CI 18-44) per 1000 VTE events. This was, however, associated with 
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an increase in major bleeding events (RR 1.44, 95% CI 0.98-2.11). Current guidelines do not 
recommend blanket thromboprophylaxis to all cancer patients.19 Therefore, it is crucial to be able to 
identify cancer-patients who are at high risk of VTE, in order to provide targeted thromboprophylaxis 
to the patients with a favorable benefit to harm ratio. Current risk prediction models for VTE among 
cancer patients, are based mainly on cancer localization, patient-related factors and laboratory 
parameters.65,66 A validation study reported, however, that these risk prediction models may be of 
limited clinical value, as they have a low potential to identify high-risk patients, as only 12% of the 
entire cancer cohort study population was considered high risk. Furthermore, these risk prediction 
models may have an insufficient capacity to predict VTE in high-risk subjects, as only 7% of the high- 





1.2.1 General pathophysiology of venous thromboembolism 
In 1856, the German scientist Rudolph Virchow proposed a triad of causes for thrombosis, 
theorizing that stasis, hypercoagulability, or vessel wall damage could lead to thrombosis (Figure 1). 
Although advances in research have provided us with more sophisticated tools to expand the triad, it 
still represents a cornerstone in our understanding of the pathophysiological mechanisms of VTE. 
A healthy and undamaged endothelium expresses various anticoagulants, such as tissue factor 
pathway inhibitor (TFPI), thrombomodulin, endothelial protein C receptor (EPCR), and heparin-like 
proteoglycans.67 Endothelial damage results in expression of tissue factor (TF) and adhesion 
molecules, which in turn results in activation of the coagulation cascade and adhesion of white blood 
cells to the endothelial surface.68 Together, factor (F) VIIa and TF, activate the extrinsic coagulation 
pathway via activation of FIX and FX. Activated FX and FVa, convert prothrombin (FII) to thrombin 
(FIIa), and ultimately lead to fibrin deposition and clot formation. A relationship between arterial 
thrombosis and blood vessel injury is well-established. Rupture of an atherosclerotic plaque exposes 
subendothelial TF, collagen and von Willebrand factor (vWF).69 The role of endothelial damage in the 
development of VTE, however, is less obvious. Sevitt reported the histological findings from 50 thrombi 
recovered from autopsies and did not find evidence of endothelial damage for most thrombi. He 
concluded that vessel wall injury may not contribute significantly to DVT, except for when associated 
with acute insults (i.e. surgery, trauma).70 However, hypoxia has been suggested as a more subtle form 
of endothelial injury, as it can promote endothelial activation and permeability.71 Endothelial 
dysfunction can result in a prothrombotic state by alterations in the balance between clot formation 
and breakdown due to decreased synthesis of nitric oxide and prostaglandin I2 and increased 
entothelin-1.72 
Hypercoagulability, or an abnormally increased tendency toward clotting, plays an important 
part in the pathogenesis of VTE. Activated factors are concentrated in areas of reduced flow, such as 
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the valve pockets.73 Hypercoagulable states may be inherited or acquired. A number of genetic defects 
influence an individual’s risk of VTE, such as single nucleotide polymorphisms (i.e. Factor V Leiden and 
prothrombin G20210A) and deficiencies in natural anticoagulants (i.e. protein C/S).73 Acquired 
hypercoagulable states include obesity, pregnancy, oral contraceptives, as well as cancer and 
chemotherapy. Hyperestrogenemia, caused by pregnancy, oral contraceptives, or hormone 
replacement therapy, results in increased hepatic synthesis of procoagulant proteins and decreased 
synthesis of anticoagulants.74 In addition, release of tissue factor from damaged tissues or tumor cells, 
can result in activation of the coagulation cascade.75 
 




 Venous thrombi most often develop in the valvular sinuses of the venous valves.76,77 An 
experimental study on dogs demonstrated that, in the absence of pulsatile flow, prolonged stasis 
resulted in severe hypoxia in the recesses of the venous sinuses.77 Immobility can result in prolonged 
blood stasis and further potentiate the hypoxia in these regions.77 As blood travels against gravity in 
the veins, some is caught in a secondary vortex of the valve sinuses (Figure 2). This leads to localized 
hypoxia in this region and promotes prothrombotic and proinflammatory processes in endothelial 
cells, as well as the recruitment and activation of leukocytes and platelets. Endothelial cells mobilize 
P-selectin and vWF on their surface, which recruit platelets and leukocytes that express TF, which then 
activates the coagulation cascade.  
 
Figure 2. The pathophysiology of DVT in the venous valves: when blood is trapped in a vortex of the 
valve pockets, it becomes desaturated. This hypoxia promotes prothrombotic processes in endothelial 
cells, leukocytes, especially monocytes (Mc), and platelets (Plt). Activated platelets and leukocytes 
bud-off procoagulant (TF positive) microparticles (MP), which can activate the coagulation cascade. 
These procoagulant microparticles have been suggested as important triggers of VTE.  
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1.2.2 Pathophysiology of cancer-related venous thromboembolism 
Virchow’s triad of endothelial damage, hypercoagulability and stasis are important features of 
cancer and they play an important role in the pathophysiology of VTE in cancer patients. Coagulation 
activation and tumor growth and progression are closely related and cancer represents a 
hypercoagulable state. Cancer cells can activate coagulation via several mechanisms including 
procoagulant and proaggregating activities, as well as proinflammatory processes (i.e. tumor necrosis 
factor alpha).78,79  Changes in hemostasis that promote thrombosis among cancer patients include 
platelet activation, FX activation by TF, reduced hepatic synthesis of anticoagulants and reduced 
clearance of activated factors.78 Furthermore, it has been demonstrated that cancer patients have 
increased markers of coagulation activation such as elevated plasma D-dimer levels.80 TF is normally 
not expressed in healthy vascular cells, although tumor cells express high levels of TF.78 Compared to 
non-cancer patients, cancer patients have significantly higher levels of TF and FVIIa, indicating 
activation of the extrinsic pathway of the coagulation cascade.81 The intrinsic pathway, however, is not 
involved in cancer-related thrombosis to the same extent, as levels of factor XIIa are only marginally 
increased in cancer patients.82 Cytotoxic drugs can also release procoagulants and cytokines from lysed 
tumor cells.83 
 Tumor invasion may result in vessel wall injury. Cancer treatment including surgery, central 
venous catheters, chemotherapy and radiotherapy can all result in endothelial damage.84 The 
endothelium can be directly damaged as a result of trauma from surgery or central venous catheter 
insertion. Chemotherapy and radiotherapy can also cause endothelial cell injury.83,85 
 Venous stasis may occur in cancer patients as a result of direct compression of nearby blood 
vessels by bulky tumors.86 Cancer patients are often immobilized as a result of surgery, treatment, or 





1.3 Risk factors 
A risk factor is defined as any attribute, characteristic, or exposure of an individual that 
increases the likelihood of developing a disease or injury. The impact of a risk factor depends on its 
prevalence and its associated relative risk.87 Venous thromboembolism is a multicausal disease, 
meaning that several factors must be present for an event to occur.87 Several inherited and acquired 
risk factors for VTE have previously been described. The complex interplay between risk factors for 
VTE may be explained by the thrombosis potential model (Figure 3).87 In this model, the thrombosis 
risk depends on an accumulation of risk factors that adds to an individual’s thrombosis potential, 
resulting in a VTE only when the joint effects of these risk factors outweighs natural anticoagulant 
properties and exceeds the thrombosis threshold. In order to prevent VTE, and therefore, improve 
survival, patient suffering, and reduce healthcare costs, we must identify those persons who are at 
high risk of developing a VTE event.   
Figure 3. The thrombosis potential model. The green line represents intrinsic factors that are stable 
over time such as Factor V Leiden (FVL), and the red line represents the effect of a risk factor that 
increases over time, like age. The orange line demonstrates the joint effects of FVL and age in 
combination with provoking factors. Provoking factors early in life may not be enough to reach the 
thrombosis threshold. However, a provoking factor later in life may exceed the thrombosis threshold 
and results in a VTE. If the thrombosis potential remains increased following a VTE event, a provoking 
factor may exceed the thrombosis threshold again and result in a recurrent VTE. 
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1.3.1. Risk factors for venous thromboembolism   
 VTE is strongly heritable. Family and twin studies propose that genetic factors account for 
approximately 60% of the VTE risk, 88 and a family history of VTE is associated with a 2 to 3-fold higher 
risk of VTE.89,90 Inherited thrombophilias are generally caused by two main mechanisms: gain-of-
function mutations and loss-of-function mutations.91 Susceptibility genes associated with VTE can be 
visualized in Table 1. In gain-of-function mutations, there is gain of function of procoagulant factors. 
Gain of function mutations can result in the increased synthesis of a normal protein (i.e. prothrombin 
G20210A), impaired breakdown or down-regulation of a normal protein (i.e. Factor V Leiden), or rarely, 
can result in the synthesis of a functionally hyperactive protein (i.e. factor IX Padua). Factor V Leiden 
(FVL) is a missense (arginine to glutamine) single nucleotide polymorphism (SNP).91 FVL heterozygosity 
is present in approximately 5 to 8% of white Americans and Europeans.92,93 FVL is thought to be 
prothrombotic by its resistance to activated protein C (APC) and also by the abnormal breakdown of 
FVIII by APC.94 Heterozygous carriers have a 2 to 5-fold higher risk of VTE, while the risk is 10- to 80-
fold higher in homozygous carriers.92 The prothrombin (PT) 20210A mutation on the prothrombin (F2) 
gene is characterized by high plasma levels of prothrombin.95 Similar to FVL, PT20210A is also 
prothrombotic by its APC resistant properties.96 The variant is present in about 1 to 2% of the 
population and is associated with a 1.5 to 3.0-fold higher risk of VTE.97,98 A non-O blood type is present 
in 60 to 70% of the population and it is associated with a 1.5 to 2.0-fold higher risk of VTE.97,99 The 
association between VTE and non-O blood groups is thought to be mediated in part by higher levels of 
vWF and FVIII, however, the association of non-O blood type and VTE remains even after adjustment 
for both factors.100 
In loss-of-function mutations, there is loss of function of an endogenous anticoagulant. Loss-
of-function mutations are generally rarer than gain-of-function mutations, and tend to be associated 
with higher risk estimates for VTE. Inherited thrombophilias that results from loss-of-function 
mutations include deficiencies in antithrombin, protein C and protein S.100 Antithrombin deficiency can 
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be a result of several gene variations.101 Antithrombin is a strong inhibitor of the coagulation cascade. 
Antithrombin deficiencies are associated with a 10 to 50-fold increased risk of VTE.98 They are, 
however, rare and the prevalence ranges from 5 to 17 per 10 000 individuals in the general 
population.98,102 Deficiencies of protein C and protein S are also rare, occurring in less than 1% of the 
general population and are associated with an approximately 10-fold increased risk of VTE.100 
Table 1. Known susceptibility genes for VTE100 
 
 In the last decades, major advances have been made in understanding the role of genetic 
factors in the risk of VTE. Several novel SNPs associated with VTE have been identified through 
genome-wide association studies (GWAS). VTE-associated SNPs identified via GWAS approaches can 
be visualized in Table 1. GWAS consists of testing the association of a huge number of SNPs with a 
phenotype in studies with large sample sizes where participants are classified first by their clinical 
manifestation(s) and not by their genotype.103 VTE-associated SNPs have been predominately located 
in or near genes encoding for proteins in the coagulation or fibrinolytic pathways and have the 
Gene  Site  Phenotype  Frequency  VTE OR  
Genes associated with VTE identified before GWAS   
F2  rs1799963  VTE  0.02  2.5  
F5  rs6025  VTE  0.05  3  
FGG  rs2066865  VTE  0.25  1.47  
ABO  rs8176719  VTE  0.3  1.5  
PROC  multiple  VTE  rare  ~10  
PROS1  multiple  VTE  rare  ~10  
SERPINC1  multiple  VTE  rare  ~10  
HIVEP1  rs169713  VTE  0.21  1.2  
Novel SNPs associated with VTE identified by GWAS  
VWF  rs1063856  Increase vWF  0.37  1.15  
TC2N  rs1884841  Increase vWF  0.44  1.27  
STXBP5  rs1039084  Increase vWF  0.46  1.11  
GP6  rs1613662  Increased platelet function  0.82  1.15  
F11  rs2289252  Increased FXI  0.41  1.35  
F11  rs2036914  Increased FXI  0.52  1.35  
C4BPB/C4BPA  rs3813948  Increased C4BP  0.08  1.18  
KNG1  rs710446  Increased aPTT  0.45  1.2  
SERPINC1  rs2227589  Decreased antithrombin  0.1  1.29  
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potential to alter the function and plasma levels of proteins.100 Bezemer and colleagues were the first 
to conduct a large-scale association genetic study on VTE.104 Their study genotyped nearly 20 000 SNPs 
in known prothrombotic genes and identified two new susceptibility loci in GP6 and F11.  The majority 
of these SNPs identified through GWAS have only a modest effect (odds ratios (ORs) ranging from 1.10 
to 1.35) on the VTE risk and alone may have limited clinical utility. However, combinations of these 
SNPs may improve the predictive ability of risk prediction models for VTE.105 A VTE risk prediction 
model incorporating established VTE-related SNPs was proposed by de Haan and colleagues.106 They 
reported that a 31-SNP and 5-SNP risk score composed of the five most strongly associated SNPs 
performed similarly. Combining non-genetic and genetic risk scores then further improved the model. 
However, the authors conclude that in order for these genetic risk scores to become useful in the 
clinical setting, high risk persons need to be identified in whom genetic profiling will be cost 
effective.106 
Classic acquired risk factors for VTE include advancing age, cancer, surgery, prolonged 
immobility, trauma, pregnancy, puerperium, and the use of oral contraceptives.107,108 Advancing age 
is a well-established risk factor for VTE, and several studies have demonstrated that the risk of VTE 
increases exponentially with age.3,22 The incidence of VTE increases from 0.6 to 0.7 per 100 000 per 
year in children to about 1 per 100 in the elderly.23,109 Accordingly, the risk of VTE is 50 to 80-fold higher 
in the older population.23  The increased risk of VTE by age may be attributed to age-related 
degeneration of the vein walls or venous valves.77 Furthermore, increased levels of procoagulants (i.e. 
fibrinogen, FV, FVII, FVIII, FIX, vWF) and inhibitors of fibrinolysis (i.e. PAI-1, TAFI) are observed with 
increasing age.110  
Obesity is another important risk factor for VTE. According to 2014 estimates from the World 
Health Organization (WHO), worldwide obesity rates have more than doubled since 1980.111 A meta-
analysis reported that obesity, defined as a body mass index (BMI) ≥30 kg/m2, is associated with a 2.3-
fold higher risk of VTE, and risk increases with increasing BMI.112 Previous work using the Tromsø Study 
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data reported that increasing BMI, waist and hip circumference, as well as weight gain were associated 
with an increased VTE risk.113,114 Obesity-driven chronic inflammation and impaired fibrinolysis may be 
major effector mechanisms on the association between obesity and VTE.115 Furthermore, excess body 
fat may physically result in impaired venous return.116  
 Hospitalization is potent risk factor for VTE. One study found that the age- and sex-adjusted 
incidence of VTE was 960 (95% CI 795-1125) per 10 000 person-years for hospitalized patients, while 
it was only 7.1 (95% CI 6.5-7.6) per 10 000 person-years among community residents.117 Furthermore, 
Heit and colleagues reported that 61% (95% CI 57-66%) of all confirmed cases of VTE could be 
attributed to institutionalization (i.e. hospital, nursing home) within the preceding three months.118 In 
this study, the number of VTE cases among medical and surgical patients was roughly equal (22 vs 24%, 
respectively), however, there are far more medical than surgical admissions. Several VTE risk factors 
can be present during hospitalization, such as surgery, immobilization and acute medical conditions. 
Recent major surgery has long been considered a strong risk factor for VTE.50 Surgical procedures 
associated with a high VTE risk include neurosurgery, major orthopedic surgeries of the leg, cancer 
surgeries of the thorax, abdomen or pelvis, and renal transplantation.119 Major surgery is associated 
with a 4 to 22-fold increased risk of VTE.50,120 In the LETS study, non-surgical hospital admissions within 
the previous year were associated with an 11-fold (OR 11.1, 95% CI 4.7-25.9) increased risk of VTE.121 
Immobilization is an important risk factor for VTE and immobility was recorded in up to 25% of patients 
with a hospital-related VTE.122 Immobilization, defined as confinement to bed or chair, was found to 
be associated with a 6-fold (95% CI 2.3-13.7) increased risk of DVT.123 Several acute medical conditions 
such as myocardial infarction, stroke, infections, congestive heart failure, and respiratory disease are 
recognized as risk factors for VTE.19,124-126 Hospitalization for an acute medical condition is associated 
with an 8-fold increased risk of VTE.127 Thromboprophylaxis guidelines are in place for hospitalized 
patients, however, studies have shown that these guidelines are often underutilized.19,128  
27 
 
1.3.2 Patient-related risk factors for venous thromboembolism in cancer 
 Several risk factors for VTE have been identified among cancer patients, and its risk 
stratification can be broadly done in patient-, cancer-, and treatment-related factors. Several acquired 
risk factors for VTE in the general population, as described above, are also risk factors for VTE in cancer 
patients. These include advancing age, obesity, immobility, comorbid conditions and inherited 
thrombophilias.  
Increasing age is a strong risk factor for VTE and cancer is more prevalent with advancing age, 
thus, it would be reasonable to assume that cancer contributes to the increased risk of VTE in the 
elderly. However, studies investigating the impact of age on the risk of cancer-related VTE have been 
inconclusive. A study using the California Cancer Registry (CCR) did not find an association between 
increasing age and overall cancer-related VTE, however, advancing age had a modest effect on VTE in 
patients with breast and ovarian cancer and non-Hodgkin’s lymphoma.52 Khorana and colleagues did 
not find an association between age and cancer-related VTE, and age is not included in the Khorana 
risk prediction model which assesses the risk of VTE in ambulatory cancer patients.65 A Danish 
population-based cohort study, however, found that the incidence rates of cancer-related VTE 
increased with increasing age.51 Furthermore, an Italian prospective study on the risk of VTE following 
cancer surgery, found that age over 60 years was associated with a 2.6-fold higher risk of VTE when 
compared to those under the age of 60.129 In the Tromsø Study, the relative risk for VTE by cancer was 
higher in younger subjects than in those over 70 years.130 However, the difference between the age-
specific population attributable risks (PAR) for cancer-related VTE was minimal between the young 
(<50 years, PAR 14%) and the elderly (>70 years, PAR 18%) subjects. These findings indicate that cancer 
may not explain a substantial proportion of the VTE events in the elderly.  
 The effect of anthropometric measures on the risk of cancer-related VTE has not been widely 
studied. Obesity, defined as a BMI ≥35 kg/m2, is one of the five predictive variables used in the Khorana 
risk model.65 In the above study, obesity was associated with an OR of 2.1 in multivariable analysis.65 
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Studies investigating the risk of VTE in patients with ovarian cancer had similar findings,131,132 while 
other studies in prostate and ovarian cancer did not find an association between obesity and VTE.133,134 
Furthermore, in the European population included in the CATS cohort, a BMI ≥35 kg/m2 was an 
infrequent observation and was not found to be associated with VTE among cancer patients.135  
 Although immobilization is a strong risk factor for VTE in the general population, it has not 
been directly studied in cancer patients. In the Tromsø Study, immobilization defined as bedrest over 
three days, wheelchair use and long-haul travel over four hours in the last 14 days, was the most 
frequent provoking factor for VTE in both non-cancer and cancer subjects, present in 19% and 23% of 
subjects, respectively.130 In a prospective observational study, bedrest lasting longer than three days 
was associated with a 4.5-fold (95% CI 2.45-7.78) increased risk of cancer-related VTE in surgical 
patients.129 Currently, primary thromboprophylaxis for prevention of VTE is only recommended in high 
risk patients, which is often based on primary cancer site and pre-treatment biomarker levels.65 Society 
guidelines, however, suggest that cancer patients with additional risk factors, such as immobilization, 
should also be considered candidates for thromboprophylaxis.19,136,137 
 Several comorbid conditions have been found to be associated with an increased risk of 
cancer-related VTE, especially if several are present simultaneously. Comorbid conditions that have 
been found to be associated with cancer-related VTE in hospitalized patients include arterial 
thromboembolism (OR 1.45, 95% CI 1.39-1.52), pulmonary disease (OR 1.37, 95% CI 1.34-1.40), and 
renal disease (1.53, 95% CI 1.49-1.58), as well as infections (OR 1.77, 95% CI 1.73-1.81) and anemia (OR 
1.35, 95% CI 1.32-1.39).56 The number of medical comorbidities has also been shown to be an 
independent risk factor for cancer-related VTE in several studies.138-141 Using the CCR study in patients 
with colorectal cancer, the presence of three of more comorbid conditions was associated with a 2-
fold (95% CI 1.7-2.3) increased risk of VTE.139 
 In recent years, major advances have been made in the understanding of genetic 
predispositions in VTE, however the effect of inherited thrombophilias on the risk of cancer-related 
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VTE has not been widely studied. The majority of genetic studies in VTE have excluded cancer patients. 
The limited number of studies on established genetic risk factors (i.e. FVL, PT 20210A) that have been 
performed on VTE in cancer have had inconsistent results, likely because of the small patient 
populations in the majority of these studies.142-146 In a case-control study using data from the Multiple 
Environmental and Genetic Assessment (MEGA) Study, FVL carriers with cancer were at a 12-fold (95% 
CI 1.6-88.1) higher risk of VTE when compared to cancer-free non-carriers.142 Using the CATS cohort, 
Pabinger and colleagues reported a 2-fold (HR 2.0, 95% CI 1.0-4.0) higher risk of VTE among cancer 
patients with the FVL mutation compared to cancer patients without.147 Small studies have 
investigated the effect of the PT 20210A mutation on the risk of cancer-related VTE, however, the 
results have been conflicting, most likely because of the lack of power due to the rarity of this 
mutation.142,143,148 Furthermore, small studies have reported an association between the non-O blood 
group (ABO rs8176719) mutation and cancer-related VTE at specific cancer sites (i.e. pancreatic, 
glioma).149-151  
 
1.3.3 Cancer-related risk factors for venous thromboembolism in cancer  
 Several cancer-related risk factors have been identified including cancer type, stage, tumor 
grade, histological type, and time since cancer diagnosis. Although the incidence of VTE by cancer type 
varies in different studies, pancreatic, brain, lung, and ovarian cancers are consistently reported as the 
highest risk cancer types.51,55,152,153 Lymphomas, myeloma, kidney, and gastrointestinal cancers are 
associated with moderate risks for VTE, while breast and prostate cancers are associated with a 
relatively low risk.51,52,56 The histological subtype of a cancer can influence the VTE risk.140,154 For 
instance, squamous cell lung cancer is associated with a lower incidence of VTE than adenocarcinoma 
of the lung, at 4.8 vs. 9.9 per 100 person years in the first half year following a cancer diagnosis.154 
 Cancer stage is strongly correlated with the risk of VTE.51,142,152 In a study using the CCR data, 
metastatic disease at cancer diagnosis was the strongest predictor of VTE.52 The risk of VTE increased 
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across progressive cancer stages (local, region and distant) at all 12 cancer sites. Another study 
reported the relative risk of VTE for stage I, II, III and IV cancers to be 2.9, 2.9, 7.5 and 17.1, 
respectively.51 Furthermore, in the MEGA study distant metastasis was associated with a 19.8-fold 
(95% CI 2.6-149.1) higher risk of VTE when compared to cancer patients without distant spread.142 
Some studies have, however, reported that the risk of VTE correlates with the rate of growth and 
spread of a cancer rather than the extent of spread (stage).139,140 Patients with cancers that rapidly 
progress from local-stage disease to widespread metastatic disease are more likely to develop a VTE, 
whereas patients with more slow-growing cancers, like breast and prostate cancer, have a significantly 
lower risk of VTE.52,155 In a CCR study of 13 031 women with ovarian cancer, 15% of the women with 
metastatic cancer at diagnosis died within three months and 15% died in the four to 12 months 
following the cancer diagnosis. The incidence of VTE was 27% and 10.7%, respectively.140 Thus, this 
study suggests that fast growing cancers, evidenced by early mortality, are associated with a higher 
risk of VTE.  
 A relationship between VTE and time since cancer diagnosis has been observed and the risk 
of VTE in cancer is not constant over the course of disease. Blom and colleagues found that the risk of 
VTE was greatest in the first three months following a cancer diagnosis.142 When compared to cancer-
free subjects, the risk in the first three months was 54-fold (95% 8.6-334.3) higher, and fell to 14.3-fold 
(95% CI 5.8-35.2) in four to 12 months after a cancer diagnosis. The risk continued to decline over time, 
although a 2-fold (95% CI 0.9-5.8) increased risk still remained in the 10 to 15 years following a cancer 
diagnosis. The high VTE risk in the first three months following a cancer diagnosis is thought to be 
related to cancer treatment (i.e. surgery, chemotherapy, central venous catheters) which is initiated 
at this time, and complications (i.e. infections, transfusions, immobilization) that often accompany 
cancer treatment, as well as tumor burden itself.  
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1.3.4 Treatment-related risk factors for venous thromboembolism in cancer 
 Cancer treatment modalities are thought to substantially affect the incidence of VTE. Surgery 
is a well-established risk factor for VTE both in cancer and cancer-free subjects. In a cohort of patients 
undergoing major surgery, cancer patients had a 2 to 4-fold higher incidence of VTE in the post-
operative period when compared to patients without cancer.119 Another study reported that cancer 
patients undergoing surgery of the abdomen and pelvis were at the highest risk of VTE.156 Blom and 
colleagues, however, found no association between surgery and VTE in cancer patients (adjusted RR 
1.0, 95% CI 0.8-1.2).157 Studies on patients with breast, colon and ovarian cancer reported a protective 
effect of major surgery on the risk of VTE, even after multivariable adjustment for age, sex, race, cancer 
stage and concomitant comorbid conditions.138-140 This may be because patients that are suitable for 
surgery have a better performance status, and/or may have non-advanced, and therefore operable 
cancer. Furthermore, surgical removal of the tumor may decrease the cancer burden and, thus, reduce 
the VTE risk. 
 Chemotherapy is a well-established risk factor for VTE. The annual incidence of VTE in patients 
receiving chemotherapy ranges from 11 to 29%.158 A nested case-control study of 625 cancer patients 
with VTE and 625 matched cancer patients without VTE demonstrated in a multivariable model that 
cancer (without chemotherapy) was associated with a 4.0-fold (OR 4.1, 95% CI 1.93-8.52) increased 
risk of VTE, while adding chemotherapy resulted in a 6.5-fold (OR 6.5, 95% CI 2.11-20.23) increased 
risk.50 In a case-crossover study, Rogers and coworkers found that the adjusted incidence rate ratio 
(IRR) for having chemotherapy in the three months before a hospitalization for VTE was 6.0-fold (IRR 
5.7, 95% CI 2.11-15.43) higher when compared to the 18 months leading up to the VTE.159 The risk of 
VTE varies by the chemotherapeutic agent used. Immunomodularly chemotherapeutics such as 
thalidomide and lenalidomide, are associated with an especially high VTE risk, in particular when they 
are used in combination with high-dose dexamethasone in the treatment of multiple myeloma.160 As 
the risk of VTE in patients with multiple myeloma is already high, thromboprophylaxis is recommended 
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to myeloma patients on this treatment.160 In a randomized controlled trial on 704 node-positive 
primary operable breast cancer patients, the cumulative incidence of VTE was 2.6% in the tamoxifen 
only treatment group, while it was 13.6% in tamoxifen combined with additional chemotherapy 
group.161 The use of bevacizumab was also reported to be associated with a relative risk of 1.3 (95% CI 
1.1-1.6) in a meta-analysis of 15 trials with patients with solid tumors.162 
 The impact of radiotherapy on the risk of cancer-related VTE has not be as extensively studied. 
Using the CATS cohort, a study of 821 cancer patients found that 47.3% had received radiotherapy, 
and the risk of VTE associated with radiotherapy was associated with a 2.3-fold (95% CI 1.2-4.4) 
increased risk of VTE.163 
 Complications of cancer and its treatment, such as central venous catheters, acute infections 
and blood transfusions are also associated with an increased risk of VTE. Central venous catheters 
(CVCs) are often used in cancer patients for the administration of chemotherapy, medications, 
hydration, and blood products. CVCs are traditionally associated with an increased incidence of upper 
extremity DVT. The incidence rates of catheter-related VTE among cancer patients ranges from 0.3% 
to 28.3%.164 A retrospective cohort study of 400 cancer patients with newly implanted ports found that 
8.5% (95% CI 6.0-11.7%) developed a symptomatic VTE.165 Of the 34 VTE events, 16 were DVTs, 16 
were PEs and 2 were both. Anemia occurs frequently in cancer, and patients are often treated with 
blood transfusions and erythropoiesis-stimulating agents. Khorana and colleagues found that of 
70 542 cancer patients, 15% received at least one red blood cell (RBC) transfusion and 3% at least one 
platelet transfusion.166 In multivariable analysis, RBC transfusions (OR 1.6, 95% CI 1.53-1.67) and 
platelet transfusions (OR 1.2, 95% CI 1.11-1.29) were independently associated with VTE. In a meta-
analysis, erythropoiesis-stimulating agents were found to be associated with a 1.67-fold (95% CL 1.35-




1.3.5 Biomarkers of venous thromboembolism in cancer  
  A biomarker, short for a biological marker, is a naturally occurring molecule, gene, or 
characteristic by which a particular pathological or physiological process or disease can be identified. 
The Food and Drug Administration (FDA) defines a biomarker as “a characteristic that is objectively 
measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention”.168 The measurement of biomarkers has 
several applications, including evaluating the risk of a disease, in the diagnostic workup of a disease, 
measuring the progress of disease, and evaluating the most effective treatment of a disease. An ideal 
biomarker has a high sensitivity and specificity, is safe and easy to measure, and is consistent across 
sex and ethnic groups. In the last decade, knowledge on cancer-related biomarkers has increased and 
is utilized in VTE risk prediction models in cancer patients.  
 Blood count parameters are of interest as biomarkers in cancer as they are measured at regular 
intervals in cancer patients. The Awareness of Neutropenia in Chemotherapy (ANC) study group 
reported an association between pre-chemotherapy platelet and leukocyte counts and hemoglobin 
levels on the risk of cancer-related VTE.65,169 They found that leukocytosis (>11 x 109/L) was associated 
with a 2.2-fold (95% CI 1.2-4.0) increased risk, thrombocytosis (>350 x 109/L) with a 1.8-fold (95% CI 
1.1-3.2) increased risk and low hemoglobin levels (<100 g/L) with a 2.4-fold (95% CI 1.4-4.2) increased 
risk of chemotherapy-associated VTE. These blood parameters are used as part of the Khorana risk 
prediction model to identify high risk cancer patients suitable for thromboprophylaxis. Furthermore, 
in the Tromsø Study pre-cancer diagnosis platelet and leukocyte counts were associated with VTE in 
cancer patients, but not in cancer-free subjects.170,171 These studies found that leukocyte counts above 
the 80th percentile (≥8.6 x 109 cells/L) were associated with a 2.4-fold (95% CI 1.44-3.87) increased risk 
of VTE in cancer.170 Pre-cancer platelet counts above the 80th percentile (≥295 x 109/L) were associated 
with a 2.0-fold (HR 1.98, 95% CI 1.21-3.23) higher risk of VTE when compared to platelet counts below 
the 40th percentile (<235 x 109/L).171 
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 Various markers of platelet and coagulation activation have also been described as biomarkers 
for cancer-related VTE. P-selectin mediates adhesion and migration of leukocytes on activated 
endothelial cells, mediates platelet-leukocyte interactions and supports fibrin.172 P-selectin levels can 
reflect a prothrombotic state.173 In the CATS cohort, elevated levels of soluble P-selectin were 
independently associated with cancer-related VTE (HR 2.6, 95% CI 1.4-4.9), even after adjustment for 
age, sex, surgery, chemotherapy, and radiotherapy.174 In this study, the cumulative probability of VTE 
at six months was 11.9% in patients with soluble P-selectin levels above the 75th percentile and 3.7% 
in those below (P = .002). However, P-selectin assays are not routinely performed in cancer patients 
which may limit its practical use.  
 D-dimer is a degradation product of cross-linked fibrin and is a global indicator of coagulation 
activation and fibrinolysis. D-dimer is a sensitive, although non-specific marker for VTE that is often 
measured in the diagnostic workup of VTE.175 D-dimer levels are also increased in malignancy.176 An 
association between D-dimer and cancer-related VTE has been demonstrated in several studies.177-179 
Again, in the CATS cohort, D-dimer levels over the 75th percentile of the entire study population was 
associated with a 2.3-fold (95% CI 1.4-4.0) increased risk of VTE.180 Ay and colleagues incorporated 
soluble P-selectin and D-dimer into the Khorana risk prediction score to identify high risk cancer 
patients that require thromboprophylaxis.66 Incorporation of these two additional parameters to the 
risk prediction model improved its accuracy to identify high risk cancer patients. 
 Prothrombin fragment 1+2 (F1+2) is released when prothrombin is cleaved to thrombin by 
activated FX. Increased levels (>75th percentile) of prothrombin F1+2 have been found to be associated 
with a 2.0-fold (95% CI 1.2-3.6) higher risk of cancer-associated VTE.163 The risk was even further 
increased when both prothrombin F1+2 and D-dimer levels were elevated (HR 3.6, 95% CI 1.4-9.5). A 
joint effect on the risk of VTE is observed when both of these biomarkers are elevated, likely because 
both are associated with a prothrombotic state.  
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 In addition, tissue factor-bearing microparticles (TF+ MPs), factor VIII and C-reactive protein 
have been found to be potential suitable biomarkers for cancer-related VTE.181-184  
 
1.3.6 Risk factors for recurrent venous thromboembolism   
 VTE is a chronic disease that frequently recurs. The cumulative incidence of VTE recurrence is 
5.2% at 30 days, 12.9% at one year and 22.8% at five years.40 In the Tromsø Study, the one-year 
cumulative incidence rate was 7.3% (95% CI 5.4-9.7) overall, 7.4% (95% CI 4.6-11.8) in provoked VTE 
and 16.3% (95% CI 9.9-25.9) in cancer-related VTE.35 Patients with a first symptomatic DVT have a 
higher risk of recurrent VTE than patients whose first event is a PE.35,185,186 
 Independent predictors for VTE recurrence include advancing age, male sex, obesity, and 
active cancer.26,40,60,186,187 A cohort study of patients in Olmsted County found that in multivariable 
adjusted analysis, the risk of VTE recurrence was increased by 17% per increase in decade of age, 24% 
per 10 point increase of body mass index and 29% in men than in women.40 In another study also using 
data from Olmsted County from 1988 to 2000, hospitalization, pregnancy, central venous catheters, 
active cancer, and respiratory infections were associated with an increased risk of VTE recurrence, 
after adjusting for interim exposures and treatment.188 Several risk factors for incident VTE, however, 
have not been found to be associated with VTE recurrence or have been found to be associated with 
a decreased risk of VTE recurrence. Recent surgery, fractures and trauma, although risk factors for 
incident VTE, are not associated with recurrent VTE.40,189 Pregnancy/puerperium, oral contraceptive 
use, and hormone replacement therapy have been found to be associated with a reduced risk of VTE 
recurrence.50,190  
 Although the risk of an incident VTE is increased in the presence of FVL and prothrombin (PT) 
20210A mutations, their role in recurrent VTE is disputed. The Leiden Thrombophilia Study found no 
association between thrombophilias (i.e. FVL, PT 20210A) and recurrent VTE,191 while other studies 
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found a significant association.41,192 Several SNPs were tested as predictors for recurrent VTE in the 
MEGA Study, and a 31-SNP and 5-SNP genetic risk score was useful in prediction of recurrent VTE.193 
Using the 5-SNP risk score (F5 rs6025, F2 rs1799963, ABO rs8176719, FGG rs2066865, and F11 
rs2036914), the six-year cumulative incidence of recurrent VTE was substantially higher in patients 
with ≥5 risk alleles (20.3%, 95% CI 16.5-24.1) versus those with ≤1 risk alleles (9.54%, 95% CI 6.7-12.1). 
However, currently, the presence of thrombophilias is not a major determinant regarding the optimal 
type or duration of anticoagulation.19 Instead, these genetic markers are often used in conjunction 
with other risk factors for risk stratification for recurrent VTE. 
A 2014 Cochrane review evaluated VTE recurrence in 11 studies including 3716 participants.194 
They reported a consistent risk reduction (RR 0.20, 95% CL 0.11-0.38) in recurrent VTE during 
prolonged treatment with vitamin K antagonists (VKAs), independent of the period elapsed since initial 
VTE. During the entire study period, a substantial increase in bleeding was observed in patients 
receiving prolonged anticoagulation (RR 2.60, 95% CI 1.51-4.49), while no reduction in mortality was 
seen (RR 0.89, 9 % CI 0.66-1.21). Over time, the absolute VTE recurrence risk decreases, while the 
major bleeding risk remains. Therefore, the benefit-harm ratio of VKAs declines progressively from the 
incident VTE event. In a systematic review, no differences in VTE recurrence rates were observed 
between VKAs and direct oral anticoagulants (DOACs).195 
 
1.3.7 Risk factors for recurrent venous thromboembolism in cancer 
 Active cancer is associated with a 2 to 9-fold higher risk of VTE recurrence. 26,59,186 Prandoni 
and co-workers found a one-year cumulative incidence of 20.7% in cancer patients receiving 
conventional anticoagulants versus 6.8% in cancer-free patients on anticoagulants.59 In the Tromsø 
Study, the cumulative incidence of cancer-related recurrent VTE is 2.7% (95% CI 1.0-7.0) at 30 days, 
8.2% (95% CI 4.3-15.7) at six months, 16.3% (95% CI 9.9-25.9) at one year and 22.0 (95% CI 16.2-41.0) 
at two years.35 Similar to non-cancer patients, the risk of recurrence is greater after a DVT as the first 
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VTE event. A study using the RIETE Registry data, reported a 2.0-fold (OR, 1.9, 95% CI 1.2-3.2) increased 
risk recurrence for PE and 2.4-fold (95% CI 2.0-3.2) for DVT.196  
The risk of recurrent VTE is not homogeneous among patients with cancer-associated 
VTE. Predictors of VTE recurrence among patients with cancer are uncertain, 197 although female sex, 
younger age, number of previous VTEs, cancer type and stage, and treatment modality have been 
associated with VTE recurrence in previous studies.197,198 The risk of recurrence has been reported to 
be present across all cancers but is highest in brain, pancreatic, lung, gastrointestinal, ovarian, and 
hematological cancers.188  
Current guidelines recommend long-term treatment with LMWH to cancer patients with a VTE 
as long as there is evidence of ongoing cancer.19 The Ottawa prognostic score is a clinical risk prediction 
tool developed to differentiate between cancer patients at low and high risk of recurrent VTE.199 The 
model includes four independent predictors: sex (+ 1 point for female sex), primary tumor site (+1 for 
lung cancer, -1 for breast cancer), cancer stage (-2 for TNM stage 1) and history of prior VTE (+1 for 
previous VTE) and patients score on a scale from -3 to 3 points. They found that patients with a score 
of 0 or less had a low risk (≤4.5%) of VTE recurrence, while patients with a score >1 were at a high risk 






1.4 Risk of cancer after venous thromboembolism 
1.4.1 VTE as a first sign of cancer 
VTE can be the first manifestation of an underlying cancer and several studies have confirmed 
that the risk of cancer is increased after a VTE.6,61,203,204 A large, Scottish population-based registry study 
of almost 60 000 participants with a VTE reported the excess risk (via standardized incidence ratios, 
SIRs) of cancer in relation to time since VTE diagnosis.205 The overall SIR for developing cancer following 
a VTE during the 19-year follow-up was 1.28 (95% CI 1.25-1.33), compared to what was expected based 
on the incidence of first cancers in the country. There was an especially high excess risk of cancer (SIR 
4.2, 95% CI 3.9-4.5) during the 1 to 6 months after a VTE event. The risk was increased across all cancer 
types, but it was highest for ovarian cancer and Hodgkin’s and non-Hodgkin’s lymphomas. A Swedish 
study also reported similar findings in terms for excess risk (SIR 3.2, 95% CI 3.1-3.4) and for cancer sites 
associated with a higher risk (liver, pancreatic, ovarian, brain, and Hodgkin’s lymphoma).6 A systematic 
review reported that among patients with an incident VTE event, 4.1% (95% CI 3.6-4.6%) were 
diagnosed with cancer within 30 days of the VTE, and 6.3% (95% CI 5.6-6.9%) within one year.206 
The risk of cancer following an incident VTE event does not differ according to the anatomical 
location of the VTE. Using the Scandinavian Thrombosis and Cancer (STAC) cohort the one-year risk of 
cancer was essentially similar for an incident event of DVT (HR 4.12, 95% CI 3.12-5.43) and PE (HR 3.97, 
95% CI 2.80-5.61).207 The risk estimates also remained equal after the first year. A large, French, 
multicenter, prospective observational study reported an overall incidence of cancer of 1.4% (95% CI 
0.9-2.1) for distal DVT and 1.5% (95% CI 0.8-2.4) for proximal DVT.208 Furthermore, a Danish study 
found that patients with superficial vein thrombosis (SVT) also have an increased risk of cancer.209 The 
SIRs for SVT were comparable to those for DVT and PE (2.46, 2.75, and 3.27, respectively).  
Patients with an unprovoked VTE are thought to be at a higher risk of developing cancer than 
those with a provoked VTE.206,210 In a systematic review, Carrier and coworkers reported a one-year 
incidence of cancer following VTE at 10% (95% CI 8.6-11.3%) for unprovoked VTE and a 2.6% (95% CI 
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1.6-3.6%) for provoked VTE.206 The definitions of provoked VTE were provided from the original studies 
and varied slightly across studies. In the STAC cohort, the risk of cancer did not vary as greatly in 
provoked and unprovoked VTE events.207 In the first year following a VTE event, the risk of cancer was 
4.47-fold (95% CI 3.43-5.83) increased in unprovoked VTE and 3.52-fold (95% CI 2.39-5.17) increased 
in provoked events in a multivariable model using age as a time-scale adjusted for sex, height, BMI, 
alcohol units per week, smoking, self-reported diabetes, higher education, and hard physical activity. 
The difference was even smaller after the first year for unprovoked (HR 1.26, 95% CI 1.04-1.54) and 
provoked (HR 1.36, 95% CI 1.05-1.74) VTE events. These results suggest that VTE may be the first sign 
of an occult cancer regardless of whether it was provoked or not. This is in accordance with the 
multicausal nature of VTE (thrombosis potential hypothesis), where several risk factors must be 
present for an event to occur. 
 
1.4.2 Screening for cancer in patients with venous thromboembolism  
 The risk of cancer is increased following a VTE, and several studies have investigated predictors 
of cancer in VTE patients. In a study using data from the RIETE Registry, several biomarkers were 
investigated as predictors for cancer within three months of a VTE event, including patient-related 
factors (i.e. age, body weight), risk factors for VTE (i.e. immobilization, surgery, prior VTE), VTE 
characteristics (i.e. DVT, PE), laboratory parameters (i.e. hemoglobin, platelet count, D-dimer), and 
treatment (i.e. LMWH, UFH).13 Age (60 to 75 years), unprovoked VTE, bilateral thrombosis and anemia 
were independent predictors of cancer in VTE patients, while no significant association was found 
between platelet counts, D-dimer levels, surgery and anticoagulant treatment. Two small retrospective 
studies, however, did find an association between D-dimer levels at VTE and an increased risk of 
cancer.211,212 
During the last years there has been an ongoing debate regarding screening for cancer in 
patients with incident VTE and if any, to which extent it should be done. Some studies have 
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demonstrated that limited screening (i.e. patient history, physical examination, routine blood work, 
chest x-ray) for cancer at VTE is adequate for the detection of most cancers, while other studies have 
suggested that additional extensive screening measures (i.e. ultrasound, CT, measurement of tumor 
biomarkers) are needed to better detect underlying cancers.206,213-216 In a Canadian randomized 
controlled trial limited cancer screening (routine blood work, chest x-ray, and screening for breast, 
cervical, and prostate cancer) was compared to limited screening in combination with an abdominal 
and pelvic CT scan.217 There was no significant difference between the number of cancers or the 
average time to diagnosis, nor in cancer-related mortality between the limited and extensive screening 
groups. A study from the Netherlands on 630 patients reported that the number of cancers and cancer-
related deaths was similar among patients who had undergone limited screening and those who had 
undergone extensive screening. A French multicenter study compared fluorodeoxyglucose (FDG) 
PET/CT cancer screening to limited screening, and found that extensive screening was not significantly 
associated with higher rates of cancer diagnosis after unprovoked VTE.218 Even though extensive 
screening may detect cancer earlier, there is no evidence of improved prognosis. Thus, current 
guidelines recommend limited screening for patients with unprovoked VTE and extensive evaluation 
only in those patients with suspicion of underlying cancer.   
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2. Aims of the thesis 
The aims of this thesis were: 
• To assess the joint effect of two single nucleotide polymorphisms, F5 rs6026 (Factor V Leiden) and 
F5 rs4524 and active cancer, on the risk of venous thromboembolism in a case-cohort study with 
subjects recruited from the general population. 
• To assess the overall and time-specific risk of VTE in cancer patients recruited from three large 
Scandinavian population-based cohorts accounting for the differential mortality between cancers. 
• To assess the risk of VTE recurrence and mortality in VTE patients with overt and occult cancer in 
a large population-based cohort study. 
• To investigate the association between plasma D-dimer levels measured at incident VTE diagnosis 
and the risk of cancer within the subsequent two years in a cohort of VTE patients recruited from 





3.1 Study populations  
3.1.1 The Tromsø Study 
The Tromsø Study is a single center, population-based cohort study with repeated health 
surveys of the inhabitants of the municipality of Tromsø. The first survey was carried out in 1974 with 
an emphasis on cardiovascular disease, however, the focus of the Tromsø Study has expanded over 
time and now includes a broad spectrum of diseases. Thus far, seven surveys have been conducted, in 
1974, 1979 to 1980, 1986 to 1987, 1994 to 1995, 2000 to 2001, 2007 to 2008, and most recently the 
seventh survey in 2015 to 2016. Paper I uses the Tromsø Study 4 to 6 surveys, while Paper II uses the 
Scandinavian Thrombosis and Cancer (STAC) cohort, which includes the Tromsø 4 Study. Papers III and 
IV use information from the first six surveys of the Tromsø Study. Tromsø 1 was conducted in 1974, 
and men aged 20 to 49 were invited and 6595 participated. Tromsø 2 invited men and women between 
the ages of 20 and 54 and 16 621 subjects participated. Tromsø 3 was conducted from 1986 to 1987 
and 21 826 people between the ages of 12 and 67 participated. The Tromsø 4 Study was conducted 
from 1994 to 1995 and a total of 27 158 subjects aged 25 to 97 years participated. Tromsø 5 was 
conducted from 2001 to 2002 and included 8130 subjects aged 30 to 89 years. Finally, Tromsø 6 was 
conducted from 2007 to 2008, and included 12 984 subjects aged 30 to 87 years. The participation 
rates for all surveys were high, with 83%, 74%, 75%, 77%, 79% and 66% of the invited population 
participating in Tromsø 1 to 6, respectively. Participants were followed up from January 1, 1994, when 
VTE registration started, until December 31, 2012 in Papers I and II, and from the date of their incident 




3.1.2 The Scandinavian Thrombosis and Cancer Cohort 
 The Scandinavian Thrombosis and Cancer (STAC) cohort is a large, population-based cohort 
comprising data from three large Scandinavian cohorts, the Tromsø 4 Study, the second Nord-
Trøndelag Health Study (HUNT 2) and the Danish Diet, Cancer and Health (DCH) study. The STAC cohort 
was used in Paper II. The Tromsø 4 survey has already been described in the above section. The HUNT 
2 Study was carried out from 1995 to 1997 in the Nord-Trøndelag County in Norway. All residents of 
this county above the age of 20 were invited to take part in the survey, and 65 237, or 69% of the 
eligible population, participated. The DCH Study was conducted from 1993 to 1997, and inhabitants 
aged 50 to 64 years living in the urban areas of Copenhagen and Aarhus, without a previous cancer 
were invited to participate. In total, 57 054, or 35% of the eligible population, attended the study. 
Study participants were followed up from the day of inclusion in the individual cohorts (1993 to 1997) 
until the end of follow-up (2007 to 2012). VTE events were identified until December 31, 2012 in 
Tromsø 4, December 31, 2007 in HUNT 2 and April 30, 2008 in DCH. Cancer diagnoses were registered 
until December 31, 2012 in Tromsø 4 and DCH and until December 31, 2008 in HUNT 2. Participants 
with a pre-baseline diagnosis of cancer or VTE were excluded from all cohorts before merging. 
Ultimately, the STAC cohort consisted of 144 952 individuals aged 19 to 101 years, without a previous 




3.2 Baseline measurements 
 Baseline data at study inclusion for the Tromsø and STAC cohorts was collected by self-
administered questionnaires, non-fasting blood samples and physical examination performed by 
trained personnel. Body weight and height were measured in subjects wearing light clothing and no 
shoes.  Body mass index (BMI) was calculated by the weight in kilograms (kg) divided by height in 
meters (m) squared (kg/m²). Information regarding history of cardiovascular disease (myocardial 
infarction, angina or stroke), diabetes mellitus, smoking status (never/former/current) and level of 
physical activity was obtained by using self-reported questionnaires. Blood samples were collected 
from an antecubital vein and analyzed at the Department of Clinical Chemistry at the University 
Hospital of North Norway.  
DNA was isolated from whole blood and stored at -70°C at the national CONOR biobank, 
located at the HUNT Biobank in Levanger, Norway. For the purpose of Paper I, two SNPs in the F5 gene 
(rs6025, rs4524) were genotyped. Genotyping was performed by using the Sequenom platform, which 
uses single-base extension followed by mass spectrometry to measure the molecular mass of the 
extended primers. Samples were genotyped using the Sequenom iPlex Gold Assay according to the 
recommended protocol, using an initial input of 10-20 ng DNA, and were analyzed using the 
MassARRAY Analyzer 4. Only genotypes with a high quality score of “A. Conservative” or “B. Moderate” 
were used. When multiple attempts were made to genotype an individual, one of the highest quality 
genotypes across all attempts was chosen for each SNP.  
 Papers III and IV included subjects with an incident VTE, and participants were followed up 
from the date of the incident VTE. Trained personnel reviewed the medical records for each VTE case 
and extracted information, which included information on clinical risk factors and laboratory markers 
using standardized forms. Information regarding comorbid conditions, clinical risk factors, and 
provoking factors in the eight weeks preceding the VTE event were extracted by review of medical 
records. D-dimer levels were measured as part of the diagnostic assessment of patients with suspected 
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VTE. The blood samples were analyzed at the Department of Clinical Chemistry at the University 
Hospital of North Norway, using the NycoCard D-Dimer (Nycomed Pharma, Oslo, Norway) assay from 
1994 to 1998, and the STA®-Liatest® D-Di FM from Stago (Diagnostica Stago, Ansieres, France) from 
1998 to 2012. In our study population, the majority (92%) of VTE events occurred during the period 
that the STA®-Liatest® D-Di FM assay was used. We performed a sensitivity analysis that was restricted 
only to these patients, and the risk estimates remained unchanged, which indicates that the two 





3.3 Outcome measures 
3.3.1 Identification and validation of venous thromboembolic events 
 Only first lifetime, symptomatic VTE events were included in the Tromsø Study and STAC 
cohorts. Each potential VTE case was reviewed and validated by trained personnel by assessment of 
each patient’s medical records. VTE events were classified as a DVT or a PE, and if DVT and PE occurred 
simultaneously, it was recorded as a PE.  
In the Tromsø Study, VTE events were recorded from January 1, 1994 until December 31, 2012. 
Three registries at the University Hospital of North Norway were used to identify VTE events during 
the follow-up: the hospital discharge diagnosis registry, the autopsy registry, and the radiological 
procedure registry. The University Hospital of North Norway is the sole hospital in the municipality, 
and it provides all hospital-based inpatient and outpatient medical care and relevant treatment in the 
region. Trained personnel reviewed the medical journals for each potential VTE case, and were blinded 
to the patient’s baseline variables. Relevant International Classification of Diseases, revision 9 (ICD-9) 
codes for the period 1994 to 1998 were 325, 415.1, 452, 453, 671.3, 671.4, and 671.9, and ICD-10 
codes for the period 1999 to 2012 were I26, I80, I81, I82, I67.6, O22.3, O22.5, O87.1, and O87.3.23 For 
the subjects that were derived from either the hospital discharge diagnosis registry or the radiological 
procedure registry, the following four criteria were required for a VTE event to be recorded; (1) the 
presence of signs and symptoms accordant with either a DVT, PE, or both; (2) objective confirmation 
by a diagnostic procedure (i.e. compression ultrasound, ventilation-perfusion scan, CT scan, pulmonary 
angiography, or autopsy); (3) a diagnosis of a DVT or PE noted by a physician in the patient’s medical 
records; and (4) initiation of therapy for the VTE (i.e. anticoagulant medication, thrombolysis, vascular 
surgery). For those subjects extracted from the autopsy registry, a VTE was only recorded when the 
autopsy report indicated VTE as the cause of death or as a significant affliction associated with the 
cause of death.  
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 In the HUNT 2 Study, VTE events were recorded from January 1, 1995 until December 31, 2007. 
VTE events were identified and validated by trained personnel by searching the hospital discharge 
diagnosis registries and radiological procedure registries from one tertiary-care hospital (St Olav’s 
University Hospital in Trondheim, Norway) and two local hospitals (Nord-Trøndelag Hospital Trust 
hospitals in Levanger and Namsos, Norway). Relevant discharge codes used to identify potential cases 
of VTE before the validation process were ICD-9 codes 415.x, 451.x, 452, 453.x, 325, 362.3, 433, 557.0, 
634–638 (with decimals 6 and 7), 639.6, 639.8, 639.9, 671.x, 673.x, 674, and 997.2, and ICD-10 codes 
I26.x, I80.x, I81, I82.x, I 63.6, I67.6, K55, H34.8, O08.x, O22.x, O87.x, and O88.x.22 A VTE event was only 
recorded if it was symptomatic, confirmed by an objective diagnostic test (i.e. ultrasound, venography, 
ventilation-perfusion scan or CT), and required treatment. 
 In the DCH Study, VTE events were recorded from December 1, 1993 until April 30, 2008. First 
lifetime VTE events were identified by linkage to the Danish National Patient Registry and the Danish 
National Death Registry by the use of participants’ civil registration numbers. Based on the available 
hospital discharge information for each participant, those with a discharge diagnosis code for VTE were 
registered (ICD-8: 450.99, 451.00, 451.08, 451.09, 451.99 and ICD-10: I26, I80.1–I80.9).219 Information 
was obtained regarding symptoms, laboratory blood testing, and diagnostics from the review of 
patient medical records. A VTE diagnosis was considered to be verified when typical clinical symptoms 
(i.e. unilateral leg swelling, leg pain and redness, dyspnea, chest pain) were combined with 
confirmatory diagnostic tests (i.e. ultrasound, venography, echocardiography, ventilation-perfusion 
scan, or CT scan). 
 
3.3.2 Identification and validation of cancer 
 First lifetime cancer diagnoses during follow-up were identified by linkage to the Cancer 
Registry of Norway (CRN) (Papers I to IV) and the Danish Cancer Registry (Paper II) by the use of 
participants’ unique national civil registration numbers, which are assigned to all people residing in the 
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Nordic countries. Cancer registration has been mandatory by law in both Norway and Denmark since 
1952 and 1987, respectively. Both registries receive information from general practitioners, hospital 
doctors, pathological laboratories, and death certificates.220,221 These cancer registries are also linked 
to the Norwegian National Cause of Death Registry and The Danish Register of Causes of Death in their 
respective countries, as well as the patient discharge diagnosis registries. Reminders are sent to 
physicians when cancer cases which have not been officially reported to the CRN are reported via 
another source (i.e. pathologist, death certificate). Evaluations of data quality have found both cancer 
registries to be valid and complete, with an estimated 98.8% completeness in Norwegian Cancer 
Registry and 95% to 98% completeness in the Danish Cancer Registry, and with 94% and 93% of 
diagnoses microscopically verified, respectively.220,221 The registries provide information regarding 
date of cancer diagnosis, primary site of the disease (ICD10 codes C00-96), tumor histology (ICO-3), 
cancer stage (localized, regional, distant, or unknown stage), and initial planned treatment. Subjects 
with non-melanoma skin cancers (ICD 191.0–191.9) were classified as cancer-free. 
 
3.3.3 Definition of active cancer 
 Proximity to cancer diagnosis is a strong predictor of VTE risk. Studies have found that nearly 
half of the cancer-related VTEs occur in the 2.5 year period starting at six months prior to a cancer 
diagnosis until two years following a cancer diagnosis.55,222,223 This observation is in accordance with 
evidence suggesting that VTE risk is closely related to the rate of cancer growth, rather than the extent 
of cancer.139 
In Paper I, we investigated the effect of prothrombotic SNPs on the risk of VTE in active cancer. 
For the purpose of our study, the active cancer period included an occult cancer period from six months 
before a cancer diagnosis and an overt cancer period which extended until two years following a cancer 
diagnosis. If a VTE event occurred during this two and a half year timeframe, then it was labeled as an 
active cancer-related VTE. Extending the cancer observational period increases the chance of dilution, 
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as VTE events that may not necessarily be caused by cancer may be included. Following the active 
cancer period, subjects with cancer were classified as having a previous cancer, since the risk of a VTE 
remains minimally increased for several years after the active cancer period. 
 In Paper III, we investigated the risk of VTE recurrence in subjects who experience an incident 
VTE during occult and overt cancer, compared to those who were cancer-free at first VTE.  In this study, 
active cancer was defined as the time ranging from one year before a cancer diagnosis until two years 
after. An incident VTE event was labeled as being related to overt cancer if it occurred within two years 
following a cancer diagnosis. Accordingly, an occult cancer-related VTE was defined as a VTE occurring 
within one year before a cancer diagnosis. The definition of occult cancer as part of active cancer in 
Paper I differed from the definition of occult cancer in Paper III as the presence of an occult cancer in 
Paper III was obtained from the patient’s medical notes and predefined as ‘one year prior to a VTE 
event’. This information was, however, not available for the sub-cohort subjects in Paper I. Increasing 
the duration of the occult cancer period from six months to 12 months could lead to a dilution of the 





4. Main results 
4.1 Paper I 
JOINT EFFECTS OF CANCER AND VARIANTS IN THE FACTOR 5 GENE ON THE RISK OF VENOUS 
THROMBOEMBOLISM 
Venous thromboembolism (VTE) is a frequent complication in cancer. Two single nucleotide 
polymorphisms (SNPs) in the factor 5 (F5) gene (rs6025 (FVL), rs4524) have previously been found to 
be associated with an increased risk of VTE in the general population. The effect of these SNPs, 
however, has not been widely investigated on the risk of VTE in cancer patients. Therefore, in a case-
cohort study, we assessed the joint effect of active cancer and these two F5 variants on VTE. Cases 
with a first VTE (n=609) and a randomly selected age-weighted sub-cohort (n=1961) were sampled 
from the general population in Tromsø, Norway. A VTE event was classified as cancer-related if it 
occurred in the period six months before to two years after a cancer diagnosis. Active cancer was 
associated with an 8.9-fold higher risk of VTE (95% CI 7.2-10.9). The risk of a cancer-related VTE was 
16.7-fold (95% CI 9.9-28.0) higher in subjects heterozygous for rs6025 compared with non-carriers of 
the FVL allele without active cancer. In subjects with active cancer the risk of VTE was 15.9-fold higher 
(95% CI 9.1-27.9) in those with one risk allele at rs4524, and 21.1-fold (95% CI 12.4-35.8) higher in 
those with two risk alleles, when compared to non-carriers without active cancer. A synergistic 
interaction, on an additive scale, was observed between active cancer and FVL (Relative excess risk 
due to interaction (RERI) 7.0; 95% CI 0.5-14.4) and F5 rs4524 (RERI 15.0; 95% CI 7.5 -29.2). The 
incidence of VTE during the initial six months following a cancer diagnosis was particularly steep in 
subjects with risk alleles at these sites.  This implies that the combination of cancer and F5 variants 




4.2 Paper II 
IMPACT OF TIME SINCE DIAGNOSIS AND MORTALITY RATE ON CANCER-ASSOCIATED VENOUS 
THROMBOEMBOLISM IN A GENERAL POPULATION – THE SCANDINAVIAN THROMBOSIS AND CANCER 
(STAC) COHORT 
VTE occurs frequently in cancer, and previous studies suggest that aggressive cancers are associated 
with the highest risk of VTE. High rates of early mortality among cancer patients with VTE may result 
in an over-estimation of the VTE risk, especially so in patients with cancers associated with high 
mortality. Competing risk for death analysis should be taken into account when the rate of death can 
differ greatly between two study groups. Therefore, we estimated the risk of VTE by cancer sites, 
accounting for the differential mortality between cancers. We used the STAC cohort which included 
144952 participants followed from 1993 to 1997 until 2008 to 2012. Incidence rates, cause-specific 
hazard ratios (HR) and sub-distribution hazard ratios (SHR) were assessed for overall cancer and by 
cancer sites according to time-intervals since cancer diagnosis. During follow-up, 14272 subjects 
developed cancer, and 567 experienced cancer-related VTE events. In cause-specific analyses, the risk 
of VTE was highest the first 6 months following a cancer diagnosis (HR 17.5, 95% CI 15.1-20.3), and 
declined rapidly thereafter. However, when mortality was taken into account, the risk was the same 
in the period 6 months before (SHR 4.8, 95% CI 3.6-6.4) and 6 months after (SHR 4.6, 95% CI 3.9-5.4) a 
cancer diagnosis. The range of the 2-year cumulative VTE incidences was substantially narrowed at all 
cancer sites after competing risk by death was taken into account (from 1 to 10% to 1 to 4%). The risk 
of VTE by cancer sites was influenced by the mortality rate and the time since cancer diagnosis. Our 
findings suggest that the cancer itself is a major contributor to VTE risk, and competing risk by death 




4.3 Paper III 
OCCULT CANCER-RELATED FIRST VENOUS THROMBOEMBOLISM IS ASSOCIATED WITH AN INCREASED 
RISK OF RECURRENT VENOUS THROMBOEMBOLISM 
Although VTE is associated with a high recurrence rate, the absolute recurrence rates in cancer-related 
VTE, particularly in occult cancer, are not well established. We aimed to investigate the risk of VTE 
recurrence in patients with occult and overt cancer-related VTE. Incident VTE events among 
participants of the Tromsø Study 1 to 6 surveys occurring in the period from 1994 to 2012 were 
included. Occult cancer was defined as cancer diagnosed within a year following a VTE, whereas overt 
cancer was defined as cancer diagnosed within the two years before a VTE. Among 733 patients with 
incident VTE, 110 had overt cancer and 40 had occult cancer. There were 95 recurrent VTE events 
during a median of 3.2 years of follow-up. The one-year cumulative incidence of VTE recurrence was 
38.6% in occult cancer, 15.5% in overt cancer, and 3.8% in non-cancer subjects. The one-year risk of 
recurrence was 12-fold (HR 12.4, 95% CI 5.9-26.3) higher in occult cancer, and 4-fold (HR 4.3, 95% CI 
2.0-9.2) higher in overt cancer, when compared with non-cancer subjects. The risk estimates for VTE 
recurrence were lowered when competing risk by death were taken into account, especially in the 
occult cancer-related VTEs, where early mortality was high. Occult cancers associated with VTE 
recurrence were typically located at pro-thrombotic sites (i.e. lung and gastrointestinal) and presented 
at advanced stages. The majority (69%) of recurrences in occult cancer occurred before or within five 
days of a cancer diagnosis, and were therefore not related to cancer treatment. Patients with an occult 
cancer-related VTE were more often diagnosed with late-stage cancers at cancer sites typically 
associated with VTE. In conclusion, our findings suggest that individuals with an incident VTE event 
during an occult cancer period had a substantially higher rate of VTE recurrence than patients with 
overt cancer and cancer-free patients. Patients with occult cancer-related incident VTE who 
experienced a VTE recurrence had a preponderance of prothrombotic and advanced cancers at 
diagnosis, suggesting that the recurrence risk can be attributed to tumor-related factors, such as tumor 
type and stage.  
53 
 
4.4 Paper IV 
D-DIMER MEASURED AT FIRST VENOUS THROMBOEMBOLISM IS ASSOCIATED WITH FUTURE RISK OF 
CANCER 
VTE can be the first sign of an underlying cancer. The risk of cancer is highest in the first year following 
a VTE but remains increased for several years. D-dimer is a fibrin degradation product, and it is used 
as part of the assessment of a suspected VTE, where low D-dimer levels are used to exclude VTE. D-
dimer levels are also elevated in cancer. The link between markedly increased D-dimer plasma levels 
at first VTE and the risk of cancer has not been widely studied. Therefore, in a cohort of VTE cases 
(n=422) recruited from the Tromsø Study, we aimed to investigate the association between plasma D-
dimer levels measured at incident VTE and the risk of cancer within the subsequent two years. D-dimer 
levels were divided into tertiles based on the D-dimer distribution: tertile 1: <2000 ng/ml, tertile 2: 
2000–5000 ng/ml and tertile 3: >5000 ng/ml. The cumulative incidence of cancer at two years was 
4.3% in tertile 1, 6.9% in tertile 2 and 15.5% in tertile 3. The one-year risk of cancer was 1.6-fold (95% 
CI 0.5–5.0) higher in subjects in tertile 2, and 3.3-fold (95% CI 1.2–9.1) higher in subjects in tertile 3, 
when compared to the lowest D-dimer tertile. The risk persisted when extending the follow-up period 
to two years. The most common cancer sites were lung, prostate, colorectal and hematological 
cancers. Subjects in the highest D-dimer tertile who developed cancer within one year, typically had a 
more advanced cancer at the time of diagnosis, and at the time of cancer diagnosis 80% of subjects in 
tertile 3 had some degree of metastases, while only 20% of patients in tertile 1 did. The risk of death 
during the first year after VTE increased across the tertiles of D-dimer, from 1.9-fold (95% CI 0.6–6.4) 
in tertile 2 to 5.7-fold (95% CI 2.0–16.5) in tertile 3, when compared to tertile 1. In conclusion, plasma 
D-dimer levels >5000 ng/ml at incident VTE are associated with a higher one- and two-year risk of 
cancer. High D-dimer levels are also associated with more advanced cancers with poor prognoses in 
these patients. As D-dimer is routinely measured in the assessment of suspected VTE, it may be a useful 
surrogate marker for the presence of an underlying cancer.   
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5. General discussion 
5.1 Methodological considerations 
5.1.1 Study design  
 The papers in this thesis use data from the Tromsø Study cohort, with Paper II using the Tromsø 
4 Study merged with two additional population-based Scandinavian cohorts. The term “cohort” is 
derived from the Latin word “cohor”. A cohort was the standard military unit of the Roman army, and 
10 cohorts made up a Roman Legion. Therefore, each cohort, consisting of between 300 to 800 soldiers 
each, could be traceable during each battle. Since then, the word cohort has been adopted into 
epidemiology to define a set of people followed over a period of time. Papers I to IV utilize data from 
a prospective population-based cohort. In a cohort study design, study participants are followed from 
the date of inclusion in the study until they are censored, either by the outcome event of interest, the 
end of the study period, or by other defined censoring events like, in our studies, death or migration. 
A well-defined population is selected and their exposure status is recorded at study entry, then the 
outcome of interested is investigated and compared in non-exposed and exposed individuals. In Paper 
I, subjects were followed from the date of inclusion in 1994 to 1995 (Tromsø 4) or 2007 to 2008 
(Tromsø 6) until the end of 2012.  In Paper II, subjects were included at study enrollment in 1993 to 
1997 and followed up until 2007 to 2012. However, in Papers III and IV, subjects were included at their 
study entry, but their follow-up began at their incident VTE event and participants were followed up 
until recurrence or a cancer diagnosis, respectively. Participants with a cancer diagnosis before 
baseline were excluded from the analysis. The observation-time for cancer-exposed subjects started 
at the cancer diagnosis date obtained from linkage to the national cancer registries, and cancer was 
treated as a time-dependent exposure. A cohort study is useful for estimating the absolute and relative 
risks of a disease. There are several advantages that cohort studies have over other observational 
studies. As the exposure, or exposures, of interest are determined before the outcome occurs, cohort 
studies have a temporal framework to assess causality, and the outcome does not influence the 
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exposure status. Several outcomes can be investigated simultaneously, for instance, in Paper IV, our 
outcome variables were both cancer and mortality following a VTE event. Furthermore, large numbers 
of participants are normally included in cohort studies, which allows for generalizability of study results 
to other populations. However, the large number of needed study participants and the long follow-up 
duration required for a cohort study, means that this study design can be expensive and time-
consuming.  
 In Paper I, we used a case-cohort study design with subjects recruited from the fourth and 
sixth surveys of the Tromsø study. A case-cohort study is a variant of a case-control study, in which the 
source population is selected from a cohort.224  Nested within a larger cohort, the study comprised of 
cases (i.e. patients with a VTE) and a randomly selected sub-cohort of individuals from the original 
cohort. The sub-cohort is meant to reflect the occurrence of the exposure in the source population. 
The case-cohort study design can be visualized in Figure 4. Similar to cohort studies, the case-cohort 
study has a clear temporal sequence of exposure and outcome, and the probability of obtaining valid 
and unbiased information from participants is high.224 In our study 660 VTE cases were included from 
the Tromsø 4 and 6 surveys, and an age-weighted sub-cohort was randomly selected from the same 
population. Due to the case-cohort design in which every person in the cohort, including the cases, has 
the same probability of being selected to the sub-cohort, 68 controls were also cases. The main 
Figure 4. Case-cohort study design 
The entire cohort is represented by 
the large outer navy blue circle. 
Within the entire cohort, cases are 
selected (represented in green) 
and a sub-cohort population 
(represented in blue) is randomly 
selected. Due to the nature of 
random selection of the sub-
cohort, cases may be included in 
the sub-cohort population. 
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advantage of the case-cohort study design over a cohort study is that full covariate data is only required 
for cases and individuals in the sub-cohort. Thus, the case-cohort design was chosen to limit the costs 
and time required for genotyping in our study. However, this study design also carries some limitations. 
In a case-cohort study it is important to consider and account for over-representation of cases in the 
sample.  In our study, the incidence rates of VTE would obviously be over-estimated. However, the 
incidence rates of cancer would also be over-estimated, as VTE and cancer are strongly associated and 
the proportion of VTE events in the sample is high. Therefore, for the calculation of absolute risks in 
Paper I, we used the number of person-years from the original cohort (sample population n=29128) as 
a basis of calculating the incidence rates of VTE and cancer.  
 
5.1.2 Bias 
 Errors in estimation can be classified as random or systematic errors. Random errors can be 
reduced as the sample size increases, however, systematic errors will remain even as the sample size 
is infinitely increased. Bias is the term for systematic errors in epidemiological research that result in 
incorrect estimates of the true effect of an exposure on the outcome.224 The effect of bias will yield 
observed results that are either over- or underestimated from the true value, depending on the type 
of systematic error.225 Biases may be introduced into a study during participant selection, data 
collection and/or data analysis. Bias may influence both the internal and external validity of a study. 
Internal validity refers to whether the inferences drawn are true to members of the source population, 
and external validity, or generalizability, refers to the validity of the inferences to individuals outside 
of the population studied.224 Selection and information bias are the two main types of bias, although 
some overlap can exist between them.  
 Selection bias occurs when there are systematic errors in the recruitment and/or retention of 
participants in a study, which can influence the association between the exposure and the outcome.226 
Selection bias are less likely to occur in cohort studies, than in, for instance, case-control studies, 
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because, in cohort studies both exposed and unexposed study participants are selected before the 
outcome actually occurs. Self-selection is a well-established issue that occurs in epidemiologic studies 
and is an important issue to acknowledge, as it can threaten the external validity of a study. Self-
selection bias arises when individuals “select themselves” into a group, causing a biased 
sample with nonprobability sampling. For instance, in the six Tromsø Study surveys, either all, or parts, 
of the population living in the municipality of Tromsø were invited to participate, and the attendance 
rates were high. Participation rates ranged from 66% in Tromsø 6 survey to 83% in Tromsø 1.227 Invited 
subjects who did not attend the Tromsø Study tended to be younger, were more often men and were 
more likely to be single.227 The younger (<40 years) and oldest (>80 years) populations had the lowest 
attendance rates. In the HUNT2 study, the attendance rate was 69%, and similar participation trends 
were observed with more women, middle-aged and elderly (50 to 70 years) attending and fewest in 
the youngest (<40 years) and oldest (>80 years) groups.228 Both VTE and cancer tend to occur more 
often in the elderly population, and under-representation of this part of the population can diminish 
the generalizability of the results for that group. In the DCH study, the population of the urban areas 
of Copenhagen and Aarhus aged 50 to 64 years was invited to participate, and 57 053 of the invited 
160 725 people attended (attendance rate 35%).229 Participants of the DCH Study were more often 
married and had a higher level of education and socioeconomic status than non-attendees. Cancer is 
often thought to be more prevalent in persons with a lower socioeconomic status, and this group is 
underrepresented in this cohort. However, the age standardized incidence rates (SIR) for cancer in 
Denmark and in the DCH study were essentially the same (SIR 0.97, 95% CI 0.92-1.0s vs. SIR 0.98, 95% 
CI 0.94-1.03, respectively).229 Thus, it is not likely that the low participation rates and higher proportion 
of non-attendees with a lower socioeconomic status and education has a significant impact on the 
validity of the analysis in this cohort. This is likely because the differences between social classes in 
Scandinavia is smaller than other parts of the world.  
 Information bias, or misclassification bias, is introduced when study participants are not 
categorized into the correct exposure or outcome group. There are two main types of misclassification 
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bias: differential and non-differential misclassification bias.224 Differential misclassification occurs 
when the probability of exposure misclassification is influenced by the actual value of other variables. 
Differential misclassification can lead to either over- or under-estimation of the true association. Non-
differential misclassification occurs when the error does not depend on the value of other variables, 
and the errors tend to be equally distributed among the cases and the non-cases. Non-differential 
misclassification tends to occur in prospective studies, as the exposure variables are not related to the 
outcome of interest, since the baseline information is collected before the outcome occurs. Non-
differential misclassification tends to bias the association towards the null hypothesis.226 In the four 
papers in this thesis, the main exposure or outcome variables are not based on self-administered 
questionnaires, but are rather extracted from the patient’s medical records by trained professionals, 
taken from well-validated National registries (i.e. cancer variable) or from laboratory testing. Thus, the 
degree of misclassification in our studies should be limited. Paper I used information obtained from 
genotyping of approximately 2500 subjects that participated in the Tromsø 4 and 6 surveys. As in all 
laboratory testing, there is always a risk of measurement error during the testing process. However, 
testing of the DNA samples was repeated if the call rates were low. In addition, SNPs that were out of 
Hardy-Weinberg Equilibrium or those with allele frequencies that were inconsistent with previous 
reports were excluded. Thus, in the unlikely event that some measurement errors did occur during this 
process, they would occur by chance and be classified as random errors and not systematic errors. We 
would expect that these random errors would only have a marginal impact on a cohort that is large in 
size like ours. Furthermore, in Paper IV, plasma D-dimer levels at incident VTE was the main exposure 
variable, and these laboratory tests may also be subject to technical measurement errors. These errors 
would, again, rather be random errors. The effect of random errors decreases as the study population 
size increases.224 We used three relatively wide tertiles for the plasma D-dimer levels and a large cohort 




 Medical surveillance bias occurs when a medically relevant exposure or treatment of an 
exposure leads to closer surveillance for the study outcome of interest.226 This can, therefore, lead to 
a higher chance of the outcome being detected in the exposed subjects. Medical surveillance bias tend 
to result in an over-estimation of the actual effect. Since the bi-directional relationship between VTE 
and cancer is well-known, the presence of either can influence the probability of the other being 
detected. In Paper II, the risk of VTE was evaluated by six-month intervals starting from one year before 
a cancer diagnosis until two years after. Cancer patients are frequently seen and examined by doctors 
and also receive frequent imaging during the diagnosis, staging, and monitoring of the malignancy. 
Thus, it is more likely that a VTE diagnosis will be made in a patient under close medical surveillance. 
However, only symptomatic VTE events were included in our studies, so this would likely not influence 
our results greatly. Although, imaging could incidentally detect subclinical VTE events that have been 
diagnosed due to overlapping symptoms with another disease (i.e. shortness of breath in a patient 
with lung cancer). In Paper IV, the risk of cancer following an incident VTE by plasma D-dimer levels is 
evaluated. If a VTE event occurs without any obvious provoking factors, a physician may investigate 
for an underlying malignancy with a more thorough history and physical examination, and sometimes, 
if appropriate with imaging. Thus, underlying cancers would be diagnosed earlier in these patients. 
This would likely have little influence on our results, as D-dimer levels at VTE do not influence cancer 
diagnostics. Although, likely negligible, both of the above issues could be present in Paper III, where 
the risk of a VTE recurrence is evaluated in patients with no cancer, occult cancer, and overt cancer. 
Where an incident VTE event could increase the chance of a cancer diagnosis, a recurrent VTE could 
increase the probability of a cancer diagnosis and finally, a cancer diagnosis could increase the 
likelihood of a recurrent VTE diagnosis.  
 
5.1.3 Competing risk of death 
 A distinctive feature of survival analysis is the concept of censoring. In prospective studies, if a 
subject is lost to follow-up, for example, due to migration, they are censored because it is unknown if 
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the outcome of interest occurs in this person or not. Death is often handled as a censoring event in 
prospective studies and death from any cause can prevent the outcome from occurring. An assumption 
of censored survival time is that it should be non-informative, meaning that at any given point in time, 
subjects who remain in the study have the same future risk of the outcome as those who are no longer 
under follow-up (i.e. censored or dropped out from the study). However, cancer patients have higher 
mortality rates than non-cancer patients and, therefore, censoring affects exposed and non-exposed 
subjects differently.  
 Competing risk regression is most often used when the occurrence of one event may alter the 
chance of another event occurring.230 Both VTE and cancer are associated with increased mortality, 
and thus, death could prevent the eventual outcome (whether its cancer or VTE) from occurring. To 
address this concern, Fine and Gray introduced a statistical model which can account for competing 
events, like death.230 In traditional analysis methods, when death occurs, the probability of a 
subsequent VTE instantly drops to zero. These competing risk of death methods do not censor patients 
on the date of death. Therefore, the ‘true’ probability of experiencing the outcome of interest can be 
presented regardless of the influence of competing mortality, which theoretically leads to unbiased 
and meaningfully interpretable results.231  
 A study performed by Ay and colleagues using the CATS cohort compared the performance of 
traditional analysis approaches, like Kaplan-Meier and Cox regression, to competing risk of death 
analysis on the risk of VTE in a cohort of cancer patients.232 They found that the risk of VTE was over-
estimated when using standard analysis methods (Kaplan-Meier and Cox regression) compared to 
competing risk of death regression in cancers with high early mortality such as pancreatic, lung, and 
gastric cancers. Whereas, in cancers associated with lower mortality rates, such as lymphomas and 
breast cancer, the difference between the methods was minimal. This study concludes that competing 
risk of death analysis should be considered for biomarker studies with high mortality, randomized trials 
with interventions with differences in death rates, non-randomized trials with differences in risk 
61 
 
factors for death between groups, and in prognostic studies (i.e. risk score development studies) that 
can have a potential impact on medical decision making.232 However, in studies investigating etiological 
questions, traditional analysis methods can be used.  
Competing risk of death analysis was implemented in Papers I to IV, as the risk of VTE (Papers 
I to III) and cancer (Paper IV) was compared in cancer patients and VTE patients with increased D-dimer 
levels, respectively, and mortality rates were expected to differ between the groups. As expected, the 
risk estimates were over-estimated using Cox regression compared to competing risk regression in 
Papers II and III. This was especially evident in patients with cancers at sites with high early mortality 
and in patients with occult cancer provoked incident VTE who tend to be diagnosed with more 
advanced-stage cancers.  
However, in Papers I and IV the risk estimates did not differ greatly between Cox regression 
and competing risk regression. When comparing the presence of risk alleles at FVL and F5 rs4524 in 
active cancer compared to cancer patients with the wild-type allele, the hazard ratios (Cox regression) 
and sub-distribution hazard ratios (competing risk regression) were nearly identical for FVL (HR 1.9 
versus SHR 1.9) and F5 rs4524 (HR 3.5 versus SHR 3.9). This is not surprising, as we are comparing 
cancer patients with the SNPs to cancer patients without, and thus, we would not expect the risk of 
death between the two groups to differ. The presence of risk alleles at FVL and F5 rs4524 is not known 
to be associated with mortality. However, when evaluating at the risk of cancer-related VTE in subjects 
with these SNPs compared to cancer-free subjects, the difference then became evident in cancer 
patients. For instance, in cancer-free subjects with F5 rs4524 the risk estimates did not differ (HR 2.3 
versus SHR 2.3), while there was substantial over-estimation in the traditional model in cancer patients 
with risk alleles at this SNP (HR 21.1 versus SHR 9.5). This difference is driven by the differences in 
mortality among cancer and non-cancer patients.  In Paper IV the HR and SHR did not differ greatly, 
even though patients in the highest D-dimer level tertile had more advanced-stage cancers at the time 
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of cancer diagnosis. This is likely explained by the short duration of follow-up in this study (one and 
two years), and that both high D-dimer levels and cancer are associated with death. 
 
5.1.4 Confounding  
 The concept of confounding refers to a situation where the association between the exposure 
and the outcome can be attributed to the influence of a third variable.226 A confounding factor is an 
extrinsic variable that correlates with both the exposure and the outcome of interest, and it is not an 
intermediate variable in the causal pathway. If confounding is present, it may weaken, strengthen or 
possibly change the direction of the association between the exposure and outcome.226 In cohort 
studies, characteristics between exposed versus non-exposed, or diseased versus non-diseased, often 
differ due to the non-randomized nature of the study design. It is important to assess all observed 
associations between exposure and outcome for possible confounders. There are several methods to 
control for confounding in cohort studies.  
The most common strategies for dealing with confounding are adjustment for and 
stratification by the confounding variables.233,234 Multivariable analysis is a statistical technique where 
potential confounding variables are included as covariates in the regression model.226 In Papers I to IV, 
the Cox regression models are adjusted for age and sex. In Paper III, when investigating the risk of VTE 
recurrence in patients with occult and overt cancer related incident VTE events, it was questioned 
whether patients in the overt cancer group were on anticoagulants for a longer duration. Therefore, 
in addition to sex and age, we adjusted our Cox model for the planned duration of anticoagulation 
therapy in non-, occult and overt cancer patients, and the risk estimates were unchanged. Thus, 
duration of anticoagulation was not a confounding variable in these groups of patients. Some variables, 
such as cancer-related factors like chemotherapy and hospitalization, may also be intermediates in the 
causal pathway. Adjusting for intermediates in the causal pathway may lead to over-adjustment and 
could potentially obscure the results.  
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 Another method for dealing with confounding is stratification.226 Stratification involves 
dividing the study population into strata, or sub-groups, based on the confounder. Stratification also 
ensures that each group of the strata receives proper representation within the cohort. However, 
stratification is not always practical when you have small numbers in each sub-group, as it can limit 
the statistical power, which can lead to insignificant results.  
In the case-cohort study that was used in Paper I, a degree of matching between the VTE cases 
and the sub-cohort was done in order to create a sub-cohort of subjects with comparable 
characteristics with regards to possible confounding variables. The sub-cohort was randomly selected 
from the entire Tromsø Study 4 to 6 cohorts, but the selected sub-cohort participants were matched 
by five-year age categories to the VTE cases. This was done as the average age for a VTE event is higher 
than the mean age of the Tromsø 4 and 6 participants that the sub-cohort was selected from.  
 In Paper II, the effect of confounding by age was accounted for by using age as a time-scale. In 
Cox regression models, time-in-study is traditionally used as a time-scale. In a time-in-study time-scale, 
subjects start follow-up at the date they are included into a study and are followed-up until the date 
they are censored, experience the outcome or until the follow-up ends. When age is used as a time-
scale, follow-up begins at the age a person is at study inclusion and their age at censoring, outcome, 
or end of follow-up is the exit-time. The risk of VTE changes more as a function of age than as a function 
of follow-up time. Accordingly, by using age as a time-scale, the risk of VTE in subjects is compared in 
subjects at the same age, instead of the same duration of follow-up.235 This method is considered 
appropriate in longitudinal studies with large enough study populations that many people at each age 
are represented.  
 Even after applying various methods to handle confounding in our analysis, a possibility for 
residual confounding remains. Residual confounding can occur when there are unknown factors that 
are associated with the exposure or outcome, unspecific definitions of confounding variables, or due 
to lack of information from insufficient or incorrect data. Experimental studies, like randomized 
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controlled studies, are the gold standard for establishing causal relationships, as the exposure of 
interest is randomly assigned to the study participants.  
 
5.1.5 Interaction 
 In epidemiology, there are two distant types of interaction: statistical interaction and biological 
interaction. Statistical interaction describes a situation where two or more risk factors modify the 
effect of each other with regard to the occurrence of a given outcome.226 This phenomenon is also 
known as effect modification. When an interaction is present, it can be approached by stratifying the 
data on the effect modifying variable. In regression analysis, the presence of statistical interaction is 
normally assessed by entering a product term into the regression model. Unlike confounding, where 
the true association may be weakened or strengthened, interaction can result in variation in the risk 
estimates across the strata.226 Biological interaction, also known as biological interdependence and 
causal interaction, is the interdependent operation of two or more causes to produce or prevent an 
effect,224 meaning that two causes are both required to precipitate a disease and the effect of one is 
biologically dependent on the presence of another. A biological interaction is not dependent on the 
underlying statistical model, as it always refers to departure from additivity.236,237  
In Paper I, we investigated for the presence of synergism between two SNPs in the F5 gene 
and active cancer on the risk of VTE. Synergism refers to the interaction of two or more elements that, 
when combined, produce a total effect greater than the sum of the individual components. We 
assessed the presence of synergism by calculating the additive interaction, which was expressed by 
the relative excess risk due to interaction, or RERI. RERI was calculated as HR11 - HR10 - HR01 + 1, where 
HR11 is the hazard ratio for both risk factors present, HR10 , the hazard ratio for the first risk factor 
present (i.e. FVL or F5 rs4525) and HR01 the hazard ratio for the second risk factor (active cancer). RERI 
values <0 signify a negative interaction, values equaling 0 indicate exact additivity, and values >0 
indicate a synergistic interaction. We also calculated the attributable proportion due to interaction 
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(AP) using the equation: AP=RERI/HR11. The AP is interpreted as the proportion of cases in the 
combined group that is due to interaction between the two exposures. An AP value <0 indicates 
negative interaction or less than additivity, and an AP value >0 indicates a positive additive interaction. 
Finally, we investigated an interaction between the F5 variants and cancer on a multiplicative scale by 
fitting the statistical interaction terms into our Cox regression model adjusted for age and sex. We 
found significant interaction between the F5 variants and cancer on the risk of VTE on an additive scale 
(biological interaction), but no interaction on a multiplicative scale (statistical interaction) was 
observed.  
 
5.1.6 External validity 
 External validity is thought to be one of the most difficult types of validity to achieve, however, 
it is at the foundation of every good epidemiological study.226 A suggested definition for external 
validity is, “External validity asks the question of generalizability: To what populations, settings, 
treatment variables and measurement variables can this effect be generalized?”238 This concept refers 
to the idea that the study results are applicable to populations, other than the one that was directly 
studied.224  
 High external validity means that our results can be generalized to the population of Tromsø 
(Papers I to IV) and Nord Trøndelag and urban Aarhus and Copenhagen (Paper II) as a whole, and then 
further to Norwegian/Scandinavian populations, or even further to other Western populations. The 
three studies included in this thesis have relatively high participation rates. The Tromsø Study is a 
population-based survey with the intent of reflecting the general population of the area, and the 
attendance rates range from 66% in Tromsø 6 to up to 83% in Tromsø 1.227 The HUNT2 study has similar 
participation rates, with 69% of the invited population attending.228 In these two studies, some groups 
are better represented than others. For instance, there were lower participation rates for the youngest 
(<40 years) and oldest (>80 years) populations and men had a lower participation rate compared to 
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women.227 It is important to be aware of the lower attendance rates among participants in these age 
groups when generalizing results. In the instance of our study, the youngest group would not be a large 
issue, as cancer and VTE are both rare in this age group, however, this could be an issue for 
generalizability of our results in the oldest group. In the DCH study, the attendance rate was 35%, and 
a higher proportion of subjects with higher education and a higher socioeconomic status participated 
in the study.229 However, the age standardized incidence rates for cancer in Denmark and in the DCH 
study were comparable.229 In addition, the age-specific IRs of cancers in both men and women in the 
Tromsø and the HUNT2 cohorts, were similar to national figures from Norway.239 Furthermore, the 
majority of the study participants in the three cohorts used in this thesis are of Caucasian ethnicity. 
Therefore, the results of our studies may not be representative to other ethnicities.  
 People that attend health surveys are often considered to be more health conscious compared 
to the general population. Additionally, subjects who are ill or institutionalized are likely unable to 
physically attend the survey site for examination or complete a questionnaire as part of a health 
survey. Individuals who developed cancer in our studies were only those who participated in these 
health surveys, so it can be appropriate to assume that these subjects are more health-aware than 
cancer-patients as a whole. People who are more health aware may, for instance, recognize symptoms 
of a cancer earlier and receive a diagnosis earlier, thereby reducing their risk for a VTE. Also, there are 
several lifestyle risk factors that can modify the effect of cancer on VTE risk, such as smoking habits, 
which may differ between survey participants and non-participants. It is important to remember, 
however, that this bias between health survey attendees and non-attendees is particularly theoretical, 
and it is not likely that it has a large effect on our results. Further, in Papers I to IV, relative risks (i.e. 
HRs) rather than absolute risks (i.e. IRs) are predominately reported, thus, our results would not be 
greatly affected.  
 The incidence of VTE and the distribution of risk factors in our cohorts is comparable to other 
similar Western populations. Both inpatient and outpatient VTE events were registered. The incidence 
67 
 
rates of VTE per 1000 person-years was 1.7 (95% CI 1.6-1.9), 1.5 (95% CI 1.4-1.6) and 1.2 (95% CI 1.1-
1.3) for the Tromsø, HUNT2 and DCH studies, respectively.240 This is similar to other studies that 
present an incidence of VTE ranging from 1 to 2 per 1000 person-years.3,22,25 Furthermore, the 
prevalence of cancer in our three cohorts appears to be similar to reports from the Norwegian Cancer 
Registry and the Danish Cancer Registry.239,240 These findings provide reassurance that both the cancer 
and VTE populations in our cohorts are representative of the general population of the Scandinavian 
countries. 
 In Paper I, we used genotyping information for two SNPs in the F5 gene (FVL and F5 rs4524). 
There are large global variations in the human genome as a result of evolutionary events such as 
migration, natural selection and genetic drift.241 Therefore, the distribution of SNPs in our population 
may vary from other populations. Furthermore, Sami are the indigenous people of the northernmost 
parts of Norway, and thus the genome, and therefore disease risk, in the area may differ from other 
regions in the country.242 We calculated the allele frequencies for FVL and F5 rs4524 in our study 
population and they were coherent with other reference western populations. We compared the 
prevalence the two SNPs to the HapMap CEU sample of Americans of Western and Northern European 
descent.243 The allele frequency of FVL was 0.042 in our cohort and 0.05 in the CEU sample, and the 
allele frequency of F5 rs4524 was 0.732 in our data and 0.736 in the CEU data. Thus, the distribution 
of FVL and F5 rs4524 are similar to reference populations and our findings on these SNPs can be 




5.2 Discussion of main results 
5.2.1 Joint effects of F5 variants and cancer on the risk of venous thromboembolism (Paper I) 
  In Paper I, we reported that two F5 gene variants (FVL and rs4524) were associated with a 
higher risk of VTE and substantially so in patients with active cancer. We observed a synergistic effect, 
on an additive scale, between these two SNPs and cancer on the risk of VTE. Previous studies have also 
reported a joint effect between FVL and cancer on the risk of VTE. Blom and colleagues reported a 2-
fold (OR 2.2, 95% CI 0.3-17.8) higher risk of VTE in cancer patients with FVL when compared to cancer 
patients without the mutation, and a 12-fold (OR 12.1, 95% CI 1.6-88.1) higher VTE risk when compared 
to cancer-free subjects without the mutation.142 In a larger study using data from the CATS cohort, 
Pabinger and coworkers also found a 2-fold (HR 2.0, 95% CI 1.0-3.97) higher risk of cancer-related VTE 
among subjects with FVL.147 Our findings are in line with both of the above studies. We found a 2-fold 
(HR 1.9, 95% CI 1.1-1.3) higher risk associated with FVL and cancer when compared to cancer patients 
without the mutation and a 17-fold (HR 16.7, 95% CI 9.9-28.0) higher risk when compared to cancer-
free subjects without risk alleles at FVL. Previous studies found that risk alleles at F5 rs4524 are 
associated with DVT in middle-aged populations, with VTE in post-menopausal women and with VTE 
during the antenatal period.104,244,245 However, to the best of our knowledge, no other studies have 
investigate the effect of F5 rs4524 on the risk of cancer-related VTE.  
Both FVL and F5 rs4524 are thought to be prothrombotic by attenuated down-regulation of 
activated factor V by activated protein C (APC).94 Previous studies have also reported that cancer is 
associated with an acquired APC resistance.246-248 Therefore, it would be likely to assume that two 
sources of APC resistance, acquired and inherited sources, would greatly increase the risk of a VTE. 
This would be comparable to the effect of oral contraceptives in persons with the FVL mutation, as 
both result in a poor response to activated protein C.249,250  
The effect of both FVL and F5 rs4524 on the risk of VTE in non-cancer and cancer was driven 
by the high DVT risk. This finding has been previously described for FVL, and the term FVL paradox 
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describes the different risk of DVT and PE in FVL carriers.251 This paradox is not observed in other 
thrombophilic defects such as PT 20210A, antithrombin deficiencies, protein C, and protein S 
deficiencies.252 Our study is the first to describe the same pattern for F5 rs4524. Several hypotheses 
have been proposed to explain this paradox. FVL carriers may have a higher risk of DVT than PE as the 
clots in these patients may be more resistant to embolization due to a stronger structure253, because 
of an impaired anti-fibrinolytic response to APC254, or simply because fatal PEs may result in fewer 
diagnoses of FVL carriers.249 
We also found that the presence of risk alleles at FVL and F5 rs4524 had an especially strong 
impact on cancer-related VTE in the time directly succeeding a cancer diagnosis. The cumulative 
incidence of VTE among cancer patients increased substantially in the first six months following a 
cancer diagnosis, and especially so in subjects with risk alleles at FVL and F5 rs4524. These findings are 
in accordance with the thrombosis potential model (Figure 5).87 The thrombosis potential model 
illustrates how several risk factors need to be present concurrently for a VTE event to occur. Alone, 
inherited risk factors may only mildly increase the VTE risk, however in the presence of cancer, the 
Figure 5. The thrombosis potential model. The green line represents the effect of FVL and the red line 
represents the effect of age on VTE. The orange line represents the joint effect of age, FVL, and provoking 
factors on the thrombosis potential. A person with the FVL mutation has a higher baseline thrombosis 
potential. The development of cancer increases the thrombosis potential substantially, but the addition 
of surgery as a method of cancer treatment, exceeds the thrombosis threshold and results in a VTE event.  
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thrombosis potential is further increased and may be enough to result in a VTE event.  Several cancer-
treatments like surgery, chemotherapy, and central venous catheters are known risk factors for VTE, 
and will further increase the thrombosis potential. These treatment-related factors and their 
complications (i.e. acute infections) may explain why there is a considerable rise in the incidence of 
VTE in the initial months following a cancer diagnosis, especially in subjects with risk alleles at FVL and 
F5 rs4524.  
FVL and F5 rs4524 are associated with a moderately high risk of cancer-related VTE, and 
discriminate patients at risk during the first six months following a cancer diagnosis. Thus, perhaps 
along with other inherited risk factors, FVL and F5 rs4525 may be attractive candidates to pursue in 
future VTE risk prediction studies in cancer patients. Further research should address whether 
information on the presence of risk alleles at traditionally prothrombotic SNPs and novel 
prothrombotic SNPs can improve the prediction of cancer-related VTE.  
 
5.2.2 Cancer-related VTE in the general population (Paper II) 
In Paper II, we investigated the risk of VTE according to time since cancer diagnosis and cancer 
sites, with and without taking competing mortality into account. In the traditional Cox regression 
model, the risk of a VTE was already increased 4-fold (HR 4.1, 95% CI 3.0-5.5) in the six months before 
a cancer diagnosis. There is then a significant increase in the VTE-risk in the first six months following 
a cancer diagnosis, with a nearly 18-fold (HR 17.5, 95% CI 15.1-20.3) higher risk of VTE, when compared 
to the reference population. After this time, the risk estimates drop substantially over time. However, 
when taking competing risk for death into account, the risk estimates were lower at every time-
interval, but especially so in the time after a cancer diagnosis. The VTE risk was essentially the same in 
the six months before (SHR 4.8, 95% CU 3.6-6.4) and six months after (SHR 4.6, 95% CI 3.9-5.4) a cancer 
diagnosis. These findings challenge results from previous reports that the apparent increased risk in 
the initial period following a cancer diagnosis is due to an accumulation of cancer-treatment (i.e. 
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chemotherapy and surgery) and cancer-complication (i.e. immobilization and infections) related 
factors. The VTE-risk was the same in the six months before and six months after a cancer diagnosis. 
Iatrogenic and other concomitant factors associated with cancer are not present at this time, as a 
cancer diagnosis was not yet made. This therefore suggests that cancer itself is a major contributor to 
the VTE-risk in cancer patients.  
Previous studies have also found that standard analysis methods (i.e. Kaplan-Meier estimator, 
log-rank test and Cox regression) generally overestimate the risk of VTE in cancer. Ay and colleagues 
reported that the magnitude of bias is proportional to the amount of competing mortality, with 
considerable bias among cancers with high mortality.232 Campigotto and colleagues performed 
simulations comparing Kaplan-Meier estimator (KM) to competing risk of death for the risk of VTE in 
cancer. Similarly, they found that KM analysis overestimated the VTE risk substantially when 
comparing a median survival time of five months to one of two months.  
 Colorectal, lung and prostate cancers accounted for the largest proportions of cancer-related 
VTE events (12.5%, 11.8% and 9.0%, respectively). Cause-specific hazard ratios for VTE were highest 
among patients with pancreatic, lung, brain, stomach, and renal cancers, and lowest among those with 
prostate and breast cancer across all time intervals. Previous studies have reported similar findings, 
with pancreatic, brain, and lung cancers consistently being associated with the highest risk.51,55,152 
However, accounting for competing risk of death showed that the risk of VTE was substantially 
overestimated at the cancer sites associated with the highest VTE risk, as they are associated with high 
rates of early mortality. Using the standard approach (cumulative hazard analysis), the two-year 
cumulative incidence of VTE ranged between 1 and 10% between all cancer sites. The cumulative 
incidences of VTE narrowed considerably and ranged from 1 to 4% between all cancer sites when 
competing risk of death was taken into account. The Khorana risk score is a risk assessment model 
which uses five clinical (primary cancer site, BMI) and laboratory parameters (hemoglobin levels and 
prechemotherapy platelet and leukocyte counts) to identify cancer patients at low (0 points), 
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intermediate (1-2 points) and high risk (≥3 points) of VTE.65 Two points are assigned for “very high risk” 
cancer sites (stomach, pancreas, brain) and one point for “high risk” cancer sites (lung, renal, 
lymphoma, gynecologic, bladder, and testicular). Therefore, cancers at sites traditionally considered 
“high risk sites” are, at a minimum, included in the intermediate risk group. Our results indicate, 
however, that the range of the cumulative incidence of VTE between cancer sites was attenuated after 
applying competing risk of death analysis, as early mortality is high in this group of patients. Therefore, 
the risk difference between cancer sites isn’t as large as previously thought. Future risk prediction 
models for cancer associated VTE should, therefore, account for competing risk of death and include 
a broader range of cancer sites. 
 Risk estimates for VTE among cancer patients decreased as the duration of follow-up was 
extended, both in Cox regression and competing risk of death analysis, although the magnitude of the 
differences was greater in the conventional analysis. The magnitude of difference between zero to six 
months of follow-up and zero to five years of follow-up was greater for cancers with high mortality, 
like pancreatic cancer (HR 52 vs. 31), than in those with low early mortality, like breast cancer (HR 5.8 
vs. 2.9). When the duration of follow-up is extended, cancers with a better prognosis may be cured or 
enter remission and thereby contribute a large proportion of cured person-time to the cancer-exposed 
group. This would ultimately result in exposure misclassification and could result in diluted risk 
estimates during long-term follow-up.  
 
5.2.3 Recurrent venous thromboembolism and mortality after overt and occult cancer related 
venous thromboembolism (Paper III) 
In Paper III, we reported that occult cancer-related VTE is associated with a higher risk of VTE 
recurrence than overt cancer and non-cancer associated incident VTE. The majority of the VTE 
recurrences in patients with occult cancer were not related to treatment-related factors, as they 
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occurred before cancer was diagnosed. Subjects with an occult cancer-related VTE were more often 
diagnosed with late-stage cancers at cancer sites typically associated with VTE. 
Even though, this was the first study to compare patients with a first VTE during a prolonged 
occult cancer period (i.e. one year) to overt and non-cancer patients, our results are in line with 
previous studies. In the RIETE registry, patients with a VTE during the three months before a cancer 
diagnosis had a 5.4-fold higher incidence of three-month recurrence.13 In a population-based study 
where active cancer was defined as 92 days before or after the first VTE, the one-year cumulative 
incidence rate of VTE recurrence was 27%, which was comparable to the one-year cumulative 
incidence of VTE among patients with active cancer in our study (23%).60  
The majority of VTE recurrences in patients with occult cancer-related VTE occurred before the 
date of cancer diagnosis (54%) or within five days of a registered date of cancer diagnosis (69%). 
Therefore, as cancer-treatment is not initiated yet at this time, as cancer is not yet diagnosed, then 
these VTE recurrences could not be precipitated by cancer treatment-related factors like 
chemotherapy and surgery. Data from two studies reported that lung, gastrointestinal, genitourinary, 
pancreatic, and brain cancers were associated with the highest risk of VTE recurrence.196,255 Similarly, 
in our study, lung, gastrointestinal, and hematological cancers, were most often diagnosed in patients 
with occult cancer and recurrent VTE. Finally, patients with occult cancer-related incident VTEs had 
more advanced cancers at the time of diagnosis, and several studies have shown that the risk of VTE 
recurrence is higher in patients with metastatic disease.196,255,256 Mortality rates were higher among 
patients with occult cancer-related incident VTE than those with a VTE secondary to overt cancer, with 
an absolute mortality rate of 58% at one year among this group of patients. This further indicates that 
the cancers in patients with occult cancer related incident VTE events are more advanced by the time 
that they are diagnosed. Previous work has shown that the biological aggressiveness of a cancer, which 
can be manifested by rate of growth or spread of a cancer, is strongly related to VTE risk.257 Several 
studies have suggested that VTE may be a marker for biologically aggressive- and fast-growing 
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tumors.52,138,139,258 Cancers that progress from local-stage disease to widespread metastatic spread are 
more likely to be associated with VTE. Thus, cancers that are fast growing are associated with a higher 
VTE risk, whereas more indolent, slow-growing cancers, like breast and prostate cancer, have a 
significantly lower risk of VTE.52,155 These findings are all in line with our findings in Papers I and II that 
the risk of cancer-related VTE appears to be driven by cancer-related factors, rather than patient- or 
treatment-related risk factors. The effect of cancer itself, or rather the rate and severity of cancer 
growth and spread, also appears to have the greatest effect on cancer-related recurrent VTE.  
As mentioned above, mortality rates in subjects with overt and occult cancer-related VTE 
during the year following the cancer diagnosis were high (42% and 60%, respectively).  Accordingly, 
when competing risk of death was taken into account, we found that the one-year recurrence risk was 
markedly lower for both overt cancer (HR 4.3 versus SHR 2.9) and occult cancer (HR 12.4 versus. SHR 
9.6).  The difference between Cox regression and competing risk of death regression was even greater 
when looking at the five-year risk of VTE recurrence in the overt and occult cancer groups. This may be 
explained by the low five-year survival in cancer, especially when cancer is complicated by VTE.259 
There is an ongoing debate regarding limited versus extensive screening for cancer in patients 
with incident VTE. In 2012, an Italian randomized study compared limited and extensive (CT chest, 
abdomen, and pelvis) cancer screening in patients with idiopathic VTE.260 They found that extensive 
screening (with CT alone or together with hemoccult) was not significantly superior in the detection of 
cancer (10.2% versus 8.2%) when compared to common practice (limited screening). Further, 
extensive screening did not significantly affect overall mortality and cancer-related mortality (-2.1%, 
95% CI -8.0-3.8%, difference in cancer-related mortality).  A randomized control trial of 854 patients 
with an unprovoked VTE compared the effectiveness of limited cancer screening (blood testing, chest 
x-ray, and screening for breast, cervical, and prostate cancer) versus limited screening in combination 
with CT scan (abdomen and pelvis) imaging.217 They found that limited screening plus CT did not lead 
to fewer missed cancers than only a limited screening strategy. They also found that there were no 
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differences in the rates of recurrent VTE and mortality between groups. A prospective concurrently 
controlled cohort study that included 630 patients from ten university hospital clinics in the 
Netherlands compared limited (baseline screening consisting of history, physical examination, basic 
laboratory tests, and chest X-ray) and extensive (limited plus chest CT scan and mammography) cancer 
screening strategies.261 There was no significant difference the number of cancer diagnoses and 
cancer-related deaths among patients who had undergone limited screening compared to extensive 
screening. A recent French multicenter study compared fluorodeoxyglucose (FDG) PET/CT cancer 
screening to limited screening. 218 They found that limited screening plus FDG PET/CT was not 
significantly associated with higher rates of cancer diagnosis after unprovoked VTE (absolute risk 
difference 3.6%, 95% CI -0.4 – 7.9). However, the risk of a subsequent cancer diagnosis was lower in 
patients who had a negative initial screening with FDG PT/CT than in patients with a negative initial 
limiting screening (0.5% versus 4.7 %, respectively). The risk of death during follow-up, however, was 
the same in both extensive and limited screening groups. In our study, even though most cancers were 
diagnosed within a short time following the incident VTE event (86% of cancers were diagnosed within 
six months), and the majority of VTE recurrence occurred before a cancer diagnosis (69% diagnosed 
with cancer before or diagnosed within five days), the mortality among these subjects was high. In fact, 
45% of the patients with an occult cancer-related incident VTE died within six months after cancer 
diagnosis. Therefore, extensive screening for cancer at incident VTE would likely not reduce the 
morbidity and mortality associated with VTE recurrence, since the recurrent events appear to be 
associated with advanced cancer stages with high early mortality that occur within a short time 
following the initial event. In fact, extensive screening could lead to patient suffering from unnecessary 
medical procedures and would put a greater burden on the healthcare system by using unwarranted 
resources. Furthermore, extensive screening for cancer at VTE recurrence would also not be of benefit 
to the patient for the above reasons. Therefore, current society guidelines recommend the use of 
limited screening strategies in patients with unprovoked VTE. More extensive screening for cancer 
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should only be performed in cases where a physician has a high suspicion of an underlying malignancy, 
and should be evaluated on an individual basis. 
 
5.2.4 D-dimer levels at venous thromboembolism and risk of subsequent cancer (Paper IV) 
 In Paper IV, we found that plasma D-dimer levels >5000 ng/ml at incident VTE were associated 
with a higher risk of subsequent cancer at one and two years. The one year risk of cancer was 1.6-fold 
(95% CI 0.5–5.0) higher in subjects in D-dimer tertile 2 (2000 to 5000 ng/ml), and 3.3-fold (95% CI 1.2–
9.1) higher in subjects in D-dimer tertile 3 (>5000 ng/ml), when compared to the lowest D-dimer tertile 
(<2000 ng/ml). The risk persisted when extending the follow-up period to two years.  
 Previous studies have reported a 2 to 4-fold higher one-year risk of cancer following a VTE 
when compared to the general population.6,13,204 The association between plasma D-dimer levels at 
incident VTE and underlying cancer has not been extensively studied, although two retrospective 
studies have been performed on this topic. A Dutch study of 218 patients found that D-dimer levels 
above 4000 µg/L at diagnosis, or during the first days of treatment for DVT, were associated with an 
increased probability of occult cancer.262 Recently, Han and colleagues investigated the predictive 
value of D-dimer for occult cancer in 169 patients with unprovoked VTE, of which 24 developed a 
subsequent cancer during a median of 5.3 years of follow-up.263 They found that D-dimer levels >4000 
mg/ml were associated with an increased risk of an occult cancer (HR 4.12, 95% CI 1.54–11.04). 
Although this study was performed in a Korean population with non-Western cancer site distribution, 
the risk estimates for cancer were similar to those in our study. However, the participants of this study 
had a notably low age at VTE diagnosis, with 44% of the VTE patients being under 60 years. The mean 
age among patients who developed cancer was 55.7 year and the incidence of cancer was highest 
among the below 60 years group.263 Furthermore, of the 34 patients who developed subsequent 
cancer, 21 (88%) were diagnosed during the same admission as the VTE diagnosis and the median time 
to cancer diagnosis of the 3 remaining cancers after the initial hospital discharge was 104 days. The 
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maximum follow-up time in this study was 8 years, and therefore it seems unusual that no further 
cancers would be diagnosed during that time.  
In our study, in patients who developed cancer within one year, the most common cancer sites 
were those of the lung and prostate and hematological cancers. Subjects who developed cancer within 
one year with the highest D-dimer levels, typically had a more advanced cancer at the time of 
diagnosis, with 80% having some degree of cancer spread. Accordingly, the mortality rates at one and 
two years were higher among those with higher plasma D-dimer levels at VTE. The one-year risk of 
death was nearly 6-fold (HR 5.7, 95% CI 2.0-16.5) in D-dimer tertile 3 compared to tertile 1. The median 
time to death was shorter in the higher D-dimer tertiles in patients who developed cancer at 1020 
days, 470 days and 206 days in tertiles 1 to 3, respectively. Correspondingly, recent studies have found 
that, independent of VTE, D-dimer is associated with mortality, and higher D-dimer levels are a 
predictor of cancer progression and poor survival.176,179,264,265 In addition, a study using data from the 
CATS cohort found that patients with high-grade tumors had higher D-dimer levels (>75th percentile, 
1.32 µg/mL) and both tumor grade and D-dimer levels were independently associated with VTE.257 
 Mortality was high in our study participants, and especially so in those with higher D-dimer 
levels at incident VTE. The relative risk of VTE among cancer patients has been shown to be 
overestimated as mortality is greater in these patients compared to the general population.232 As the 
presence of a competing event (i.e. death) may alter the chance of another event occurring (i.e. cancer) 
Therefore, we performed competing risk of death analysis using the Fine-Gray model.230 Unlike in 
Papers I, II and III, where the difference between the traditional Cox regression model and the 
competing risk model was large, in this study, the risk estimates were essentially unchanged when 
competing risk of death was taken into account. This may simply be explained by the short duration of 
follow-up in this study. As the follow-up time is extended from one year to two years, the difference 
between the HR and SHR increases slightly. Additionally, as both cancer and high D-dimer levels are 




• We found that two F5 gene single nucleotide polymorphisms, FVL and F5 rs4524, were 
associated with a higher risk of VTE, and the risk increased per each additional risk allele at 
these sites. The F5 SNPs and active cancer displayed synergism, on an additive scale, on the 
risk of VTE.  The effect was greater on the risk of DVT than PE in non-cancer and cancer. The 
incidence of VTE among cancer patients increased substantially in the six months following a 
cancer diagnosis, and especially so in patients with the presence of risk alleles at FVL and F5 
rs4524.  
 
• In traditional Cox regression models, the risk of VTE is highest the first six months after cancer 
diagnosis and declines rapidly thereafter.  However, when mortality is taken into account, the 
risk in the period six months before and after cancer diagnosis is similar. This suggests that the 
cancer itself is a major contributor to VTE risk and that competing risk by death should be 
taken into account when exploring VTE risk in cancer. The risk of VTE by cancer sites was 
heavily influenced by mortality rates and the time since cancer diagnosis. Thus, future risk 
prediction models evaluating risk of VTE among cancer patients should take competing risk of 
death into account and should address a wider range of cancer sites. 
 
• We found that patients with an incident VTE event during an occult cancer period had a 
substantially higher rate of VTE recurrence than those with overt cancer and those without 
cancer. Patients with an occult cancer at incident VTE who experienced a VTE recurrence more 
often had prothrombotic and advanced cancers at diagnosis. Furthermore, the majority of VTE 
recurrences in the occult cancer group were not treatment-related as they occurred either 
before or within five days of a cancer diagnosis. Our findings suggest that the recurrence risk 




• We found that plasma D-dimer levels above 5000 ng/ml at incident VTE were associated with 
a higher risk of subsequent cancer at one and two years. Mortality was greater among subjects 
who had higher D-dimer levels at VTE diagnosis. Subjects with higher D-dimer levels at VTE 
diagnosis who developed cancer within one year, typically had more advanced cancer at the 
time of diagnosis.  D-dimer levels are routinely measured during the diagnostic workup of a 
suspected VTE. Therefore, D-dimer may be a useful biomarker to consider when evaluating 





7. Implications of results and further perspectives 
 Cancer is a major risk factor for VTE and the incidence of VTE among cancer patients is 
increasing.55 Risk stratification of VTE among cancer patients can be broadly done in patient-, 
treatment- and cancer-related factors. Patient-related risk factors, such as inherited thrombophilias, 
influence the risk of cancer-related VTE. We found that two F5 gene variants and active cancer had a 
synergistic effect on the risk of VTE (Paper I).  The cumulative incidence of VTE increased substantially 
in the first six months following a cancer diagnosis, and especially so in patients with risk alleles at FVL 
and F5 rs4524 (Paper I), which is likely due to cancer treatment-related factors, such as surgery, 
chemotherapy, and central venous catheters. Throughout this thesis, we have demonstrated that 
cancer-related risk factors appear to play a strong role on the risk of incident and recurrent VTE. 
Cancer-related factors such as the primary cancer site (i.e. lung, gastrointestinal, hematological), 
advanced cancer stage, and time since cancer diagnosis appear to be the main contributors of the VTE 
risk in cancer. Our findings that the VTE risk is equal in the six months before and six months after a 
cancer diagnosis (Paper II), that late-stage cancer at diagnosis is a common feature in occult and overt-
cancer related VTE (Paper III), and that the majority of occult cancer related incident recurrences occur 
before a cancer diagnosis is made (Paper III) reinforce this assumption. Further, we found that 
competing risk by death overestimates the VTE risk when traditional analysis methods like Cox 
regression and the Kaplan-Meier estimator are used.  
 Even though cancer patients are at a high risk of VTE and VTE associated mortality, current 
international guidelines do not recommend prophylactic anticoagulation to all ambulatory cancer 
patients without additional risk factors due to an uncertain benefit to harm (i.e. anticoagulation-
related bleeding risk) ratio.127,266 Thus, it is vital to recognize patients that are at high risk of cancer 
associated VTE, in order to identify those who would most benefit from thromboprophylaxis. Current 
risk prediction scores are thought to have limited clinical usefulness as they have a low potential to 
identify high-risk patients and a poor ability to predict VTE in the high-risk subjects.65 These models 
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only include limited clinical risk factors and are not generalizable to all populations. For instance, 
although more common in North American populations, patient characteristics like a BMI >35 kg/m2 
will not be a common finding in Western European populations. In fact, in the CATS cohort a BMI >35 
kg/m2 was a rare finding and was not found to be associated with VTE.135 In Paper I, we found a 
synergistic effect between two SNPs in the F5 gene (FVL and F5 rs4524) and active cancer on the risk 
of VTE. These SNPs particularly discriminated patients at risk during the first six months after a cancer 
diagnosis, and thus could be evaluated at cancer diagnosis. Therefore, these SNPs, and other novel 
genomic and proteomic risk factors, may be attractive candidates to pursue in future research on 
prediction models of VTE risk in cancer patients. As demonstrated by the results of this thesis and other 
studies, future cancer associated risk prediction models should also account for competing-risk by 
death, as early mortality is high in this group of patients. Future models should also explore further 
clinical risk factors and include a broader range of cancer sites.  
 VTE is associated with both short- and long-term cancer. Currently, extensive screening for 
cancer in unprovoked VTE is not widely recommended. We have found that the risk of one- and two-
year cancer is especially high in patients with higher plasma D-dimer levels at incident VTE. As D-dimer 
levels are routinely taken during the diagnostic work-up for VTE, it may be a useful surrogate marker 
for the presence of an underlying malignancy. Moreover, further studies are warranted to explore 
additional existing (i.e. C-reactive protein, platelet, and leukocyte count) and novel (i.e. SNPs, 
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